T-cell invigoration to tumour burden ratio associated w

Nature

545, 60-65

DOI: 10.1038/nature22079

Citation Report

#	Article	IF	Citations
1	Reinvigorated T-cell numbers counterbalance tumour burden. Nature Reviews Clinical Oncology, 2017, 14, 329-329.	12.5	0
2	Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma. Oral Oncology, 2017, 73, 65-69.	0.8	40
3	Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). International Journal of Oncology, 2017, 51, 1357-1369.	1.4	340
4	Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses. Immunological Reviews, 2017, 280, 126-148.	2.8	325
5	Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes. Cellular Immunology, 2017, 319, 3-9.	1.4	72
6	Ultrasound-based follow-up does not increase survival in early-stage melanoma patients: A comparative cohort study. European Journal of Cancer, 2017, 85, 59-66.	1.3	22
7	CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation. Current Topics in Microbiology and Immunology, 2017, 410, 99-126.	0.7	91
8	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10202-10207.	3.3	438
9	Case series of pleomorphic carcinomas of the lung treated with nivolumab. Thoracic Cancer, 2017, 8, 724-728.	0.8	39
10	The immune contexture in cancer prognosis and treatment. Nature Reviews Clinical Oncology, 2017, 14, 717-734.	12.5	1,590
11	Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell, 2017, 170, 1120-1133.e17.	13.5	960
12	KEYNOTE-006: a success in melanoma, but a long way to go. Lancet, The, 2017, 390, 1816-1817.	6.3	1
13	The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade. Cancer Immunology Research, 2017, 5, 767-777.	1.6	120
14	Lenalidomide as secondâ€line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy. Alimentary Pharmacology and Therapeutics, 2017, 46, 722-730.	1.9	12
15	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. Current Oncology Reports, 2017, 19, 64.	1.8	106
16	Emergence of High-Avidity Melan-Aâ€“Specific Clonotypes as a Reflection of Antiâ€“PD-1 Clinical Efficacy. Cancer Research, 2017, 77, 7083-7093.	0.4	20
17	Notable advances 2017. Nature Medicine, 2017, 23, 1387-1389.	15.2	0
18	Emerging Concepts Targeting Immune Checkpoints in Cancer and Autoimmunity. Current Topics in Microbiology and Immunology, 2017, , .	0.7	1

#	Article	IF	Citations
19	De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncology, The, 2017, 18, e731-e741.	5.1	568
20	Adoptive cell therapy using PD-1+ myeloma-reactive T cells eliminates established myeloma in mice. , 2017, 5, 51.		23
21	Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors. Cytokine and Growth Factor Reviews, 2017, 36, 5-15.	3.2	48
22	Cordycepin and a preparation from Cordyceps militaris inhibit malignant transformation and proliferation by decreasing EGFR and IL-17RA signaling in a murine oral cancer model. Oncotarget, 2017, 8, 93712-93728.	0.8	28
23	Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells. Medical Sciences (Basel, Switzerland), 2017, 5, 28.	1.3	22
24	Making cancer immunotherapy a surer bet. Nature, 2017, 552, S72-S73.	13.7	6
25	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. Frontiers in Immunology, 2017, 8, 1597.	2.2	225
26	Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. JCO Precision Oncology, 2017, 2017, 1-13.	1.5	44
27	Size/Charge Changeable Acidityâ€Responsive Micelleplex for Photodynamicâ€Improved PDâ€L1 Immunotherapy with Enhanced Tumor Penetration. Advanced Functional Materials, 2018, 28, 1707249.	7.8	147
28	The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy. Cancer Immunology, Immunotherapy, 2018, 67, 1011-1022.	2.0	36
29	PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cellâ€“Driven Antitumor Immunity. Clinical Cancer Research, 2018, 24, 2383-2394.	3.2	84
30	Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment. Endocrine-Related Cancer, 2018, 25, R303-R318.	1.6	126
31	Optimizing therapy in advanced-stage Hodgkin lymphoma. Blood, 2018, 131, 1679-1688.	0.6	22
32	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clinical Cancer Research, 2018, 24, 4960-4967.	3.2	222
33	Targeting Wnt/Î²-Catenin Signaling for Cancer Immunotherapy. Trends in Pharmacological Sciences, 2018, 39, 648-658.	4.0	159
34	Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8+ T Cells. Immunity, 2018, 48, 773-786.e5.	6.6	150
35	Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer Cell, 2018, 33, 581-598.	7.7	393
36	Mass cytometry: a powerful tool for dissecting the immune landscape. Current Opinion in Immunology, 2018, 51, 187-196.	2.4	80

#	Article	IF	Citations
37	Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma. Annals of Oncology, 2018, 29, 1569-1574.	0.6	44
38	Strategies to overcome HBV-specific T cell exhaustion: checkpoint inhibitors and metabolic re-programming. Current Opinion in Virology, 2018, 30, 1-8.	2.6	36
39	A roadmap towards personalized immunology. Npj Systems Biology and Applications, 2018, 4, 9.	1.4	43
40	Ratio of Immune Response to Tumor Burden Predicts Survival Via Regulating Functions of Lymphocytes and Monocytes in Diffuse Large B-Cell Lymphoma. Cellular Physiology and Biochemistry, 2018, 45, 951-961.	1.1	34
41	Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective. Immunotherapy, 2018, 10, 221-234.	1.0	7
42	Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2018, 378, 449-459.	13.9	1,951
43	Liver sampling: a vital window into HBV pathogenesis on the path to functional cure. Gut, 2018, 67, gutjnl-2017-314873.	6.1	40
44	Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science, 2018, 359, 926-930.	6.0	1,872
45	14-3-3Î¶ delivered by hepatocellular carcinoma-derived exosomes impaired anti-tumor function of tumor-infiltrating TÂlymphocytes. Cell Death and Disease, 2018, 9, 159.	2.7	96
46	Increased diversity with reduced â€œdiversity evennessâ€•of tumor infiltrating T-cells for the successful cancer immunotherapy. Scientific Reports, 2018, 8, 1058.	1.6	51
47	Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer Journal (Sudbury, Mass), 2018, 24, 47-53.	1.0	287
48	Nivolumab for the treatment of urothelial cancers. Expert Review of Anticancer Therapy, 2018, 18, 215-221.	1.1	18
49	Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab. Clinical Lung Cancer, 2018, 19, 280-288.e4.	1.1	45
50	Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Cytotherapy, 2018, 20, 394-406.	0.3	89
51	LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. Cell, 2018, 172, 825-840.e18.	13.5	312
52	Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. Oncologist, 2018, 23, 410-421.	1.9	23
53	Improving immuneâ€“vascular crosstalk for cancer immunotherapy. Nature Reviews Immunology, 2018, 18, 195-203.	10.6	340
54	Mechanisms of resistance to immune checkpoint inhibitors. British Journal of Cancer, 2018, 118, 9-16.	2.9	944

#	Article	IF	Citations
55	High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nature Medicine, 2018, 24, 144-153.	15.2	564
56	Inhibitors of the PD-1 Pathway in Tumor Therapy. Journal of Immunology, 2018, 200, 375-383.	0.4	112
57	Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms. Annals of Oncology, 2018, 29, 301-310.	0.6	98
58	Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma. International Immunology, 2018, 30, 13-22.	1.8	74
59	High-Dimensional Profiling of Tumor-Specific Immune Responses: Asking T Cells about What They â€œSeeâ€• in Cancer. Cancer Immunology Research, 2018, 6, 2-9.	1.6	15
60	Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets. Oncology Research and Treatment, 2018, 41, 298-304.	0.8	8
61	Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma. Cancer, 2018, 124, 3819-3829.	2.0	39
62	TK Inhibitor Pazopanib Primes DCs by Downregulation of the Î²-Catenin Pathway. Cancer Immunology Research, 2018, 6, 711-722.	1.6	47
63	Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. Immunity, 2018, 48, 417-433.	6.6	416
64	Hazards of Hazard Ratios â€” Deviations from Model Assumptions in Immunotherapy. New England Journal of Medicine, 2018, 378, 1158-1159.	13.9	79
65	Immune signatures predicting responses to immunomodulatory antibody therapy. Current Opinion in Immunology, 2018, 51, 91-96.	2.4	7
66	Single-cell technologies for profiling T cells to enable monitoring of immunotherapies. Current Opinion in Chemical Engineering, 2018, 19, 142-152.	3.8	11
67	Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. Cancer Immunology, Immunotherapy, 2018, 67, 311-325.	2.0	40
68	Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value. Clinical Cancer Research, 2018, 24, 407-419.	3.2	203
69	Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Annals of Oncology, 2018, 29, 71-83.	0.6	253
70	CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cellular and Molecular Life Sciences, 2018, 75, 689-713.	2.4	351
71	The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors. OncoImmunology, 2018, 7, e1386362.	2.1	62
72	Immune checkpoint blockade in infectious diseases. Nature Reviews Immunology, 2018, 18, 91-104.	10.6	407

#	Article	IF	Citations
73	Emerging biomarkers for cancer immunotherapy in melanoma. Seminars in Cancer Biology, 2018, 52, 207-215.	4.3	42
74	The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy. Annals of the Rheumatic Diseases, 2018, 77, 162-164.	0.5	39
75	Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discovery, 2018, 8, 196-215.	7.7	392
76	Immune checkpoint inhibitors in advanced nonâ€“small cell lung cancer. Cancer, 2018, 124, 248-261.	2.0	94
77	Feasibility of monitoring advanced melanoma patients using cellâ€free <scp>DNA</scp> from plasma. Pigment Cell and Melanoma Research, 2018, 31, 73-81.	1.5	25
78	Reply to S.C. Formenti et al. Journal of Clinical Oncology, 2018, 36, 2662-2663.	0.8	2
79	Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2018, 36, 1611-1618.	0.8	448
80	Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. Journal of Clinical Oncology, 2018, 36, 3450-3458.	0.8	55
81	The 46th David A. Karnofsky Memorial Award Lecture: Oligometastasisâ€”From Conception to Treatment. Journal of Clinical Oncology, 2018, 36, 3240-3250.	0.8	49
82	Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC. Translational Lung Cancer Research, 2018, 7, 691-702.	1.3	8
83	Immune profiling of microsatellite instability-high and polymerase Îµ (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy. Journal of Gastrointestinal Oncology, 2018, 9, 404-415.	0.6	49
84	Combining radiation plus immunotherapy to improve systemic immune response. Journal of Thoracic Disease, 2018, 10, S468-S479.	0.6	46
85	Combining stereotactic body radiation therapy with immunotherapy: current data and future directions. Translational Lung Cancer Research, 2018, 8, 107-115.	1.3	40
86	PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. Cancer Cell, 2018, 34, 775-791.e3.	7.7	170
87	Combination of PD-1 blockade and RetroNectin^{Â®}-activated cytokine-induced killer in preheavily treated non-small-cell lung cancer: a retrospective study. Immunotherapy, 2018, 10, 1315-1323.	1.0	6
88	Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nature Medicine, 2018, 24, 978-985.	15.2	1,044
89	Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. Frontiers in Medicine, 2018, 5, 351.	1.2	67
90	Efficacy and safety of PD1/PDL1 blockades versus docetaxel in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis. OncoTargets and Therapy, 2018, Volume 11, 8623-8632.	1.0	13

#	Article	IF	Citations
91	A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor. PLoS ONE, 2018, 13, e0208422.	1.1	14
92	Organoid Modeling of the Tumor Immune Microenvironment. Cell, 2018, 175, 1972-1988.e16.	13.5	870
93	Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. , 2018, 6, 141.		214
94	Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy. , 2018, 6, 131.		35
95	Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-Î³ and IL-12. Immunity, 2018, 49, 1148-1161.e7.	6.6	639
96	Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. OncoImmunology, 2018, 7, e1468956.	2.1	88
97	Advanced model systems and tools for basic and translational human immunology. Genome Medicine, 2018, 10, 73.	3.6	68
98	Overview of Microsatellite Instability and Immune Checkpoint Inhibitors in Colorectal Cancer. Current Colorectal Cancer Reports, 2018, 14, 167-174.	1.0	0
99	RNAi-Mediated Î²-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade. Molecular Therapy, 2018, 26, 2567-2579.	3.7	79
100	Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application. Cancer Immunology Research, 2018, 6, 1122-1128.	1.6	81
101	Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences. Frontiers in Pharmacology, 2018, 9, 1050.	1.6	48
102	Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. , 2018, 6, 99.		129
103	We Are All Connected: Modeling the Tumor-Immune Ecosystem. Trends in Cancer, 2018, 4, 655-657.	3.8	8
105	Pan-tumor genomic biomarkers for PD-1 checkpoint blockadeâ€“based immunotherapy. Science, 2018, 362, .	6.0	1,575
106	Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine. Journal of Thoracic Disease, 2018, 10, 1294-1299.	0.6	4
107	Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again. Genome Medicine, 2018, 10, 79.	3.6	36
108	Harnessing the immune system in glioblastoma. British Journal of Cancer, 2018, 119, 1171-1181.	2.9	138
109	Targeting IFNÎ± to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance. Nature Communications, 2018, 9, 4586.	5.8	60

#	Article	IF	Citations
110	Bone marrow infiltrated Lnc-INSR induced suppressive immune microenvironment in pediatric acute lymphoblastic leukemia. Cell Death and Disease, 2018, 9, 1043.	2.7	25
112	A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. British Journal of Cancer, 2018, 119, 1200-1207.	2.9	83
113	Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. British Journal of Cancer, 2018, 119, 950-960.	2.9	133
114	Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer. OncoTargets and Therapy, 2018, Volume 11, 6505-6524.	1.0	47
115	Nobel goes to immune checkpointâ€"Innovative cancer treatment by immunotherapy. Science China Life Sciences, 2018, 61, 1445-1450.	2.3	3
116	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell, 2018, 175, 998-1013.e20.	13.5	1,260
117	Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy. Cancer Immunology, Immunotherapy, 2018, 67, 1845-1851.	2.0	28
118	The hallmarks of successful anticancer immunotherapy. Science Translational Medicine, 2018, 10, .	5.8	419
119	Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC). Cancer Immunology, Immunotherapy, 2018, 67, 1825-1832.	2.0	86
120	T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient. Cancer Immunology, Immunotherapy, 2018, 67, 1767-1776.	2.0	51
121	Strategies for Predicting Response to Checkpoint Inhibitors. Current Hematologic Malignancy Reports, 2018, 13, 383-395.	1.2	23
122	Rheumatic immune-related adverse events from cancer immunotherapy. Nature Reviews Rheumatology, 2018, 14, 569-579.	3.5	162
123	Novel Systemic Treatments in High Grade Ovarian Cancer. , 0, , .		0
124	TCF1 expression marks self-renewing human CD8+ T cells. Blood Advances, 2018, 2, 1685-1690.	2.5	87
125	Chromosome Yâ€"encoded antigens associate with acute graft-versus-host disease in sex-mismatched stem cell transplant. Blood Advances, 2018, 2, 2419-2429.	2.5	11
126	Pembrolizumab-induced acute thrombosis. Medicine (United States), 2018, 97, e10772.	0.4	42
127	The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients. Cancer Biomarkers, 2018, 22, 467-476.	0.8	33
128	Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy. Medical Hypotheses, 2018, 116, 111-113.	0.8	19

#	Article	IF	Citations
129	Dominant-Negative TGF-Î² Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. Molecular Therapy, 2018, 26, 1855-1866.	3.7	406
130	Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. Thyroid, 2018, 28, 945-951.	2.4	111
131	Long-Term Persistence of Exhausted CD8ÂT Cells in Chronic Infection Is Regulated by MicroRNA-155. Cell Reports, 2018, 23, 2142-2156.	2.9	84
132	Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8ÂT Cells. Immunity, 2018, 48, 1029-1045.e5.	6.6	250
133	Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature, 2018, 557, 575-579.	13.7	942
134	Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade. ELife, 2018, 7, .	2.8	98
135	Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction. Investigational New Drugs, 2018, 36, 1138-1142.	1.2	13
136	Vaccine immunotherapy with ARNAX induces tumorâ€specific memory T cells and durable antiâ€tumor immunity in mouse models. Cancer Science, 2018, 109, 2119-2129.	1.7	22
137	Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms. Mammalian Genome, 2018, 29, 866-878.	1.0	10
138	Combination of checkpoint inhibitors with other agents as a strategy to improve anti-cancer effect â€“ a glimpse to the future. Expert Opinion on Investigational Drugs, 2018, 27, 569-572.	1.9	4
139	Investigation of antitumor activities of trastuzumab delivered by PLGA nanoparticles. International Journal of Nanomedicine, 2018, Volume 13, 957-973.	3.3	53
140	The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one. Cancer Treatment Reviews, 2018, 70, 41-46.	3.4	21
141	Liquid Biopsy for Advanced Non-Small Cell LungÂCancer (NSCLC): A Statement Paper from theÂIASLC. Journal of Thoracic Oncology, 2018, 13, 1248-1268.	0.5	515
142	Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma. Frontiers in Immunology, 2018, 9, 1786.	2.2	29
143	CD4+ T cell help in cancer immunology and immunotherapy. Nature Reviews Immunology, 2018, 18, 635-647.	10.6	1,030
144	Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nature Reviews Clinical Oncology, 2018, 15, 639-650.	12.5	152
145	Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors. Journal of Cancer, 2018, 9, 205-212.	1.2	9
146	Immune Repertoire Sequencing Using Molecular Identifiers Enables Accurate Clonality Discovery and Clone Size Quantification. Frontiers in Immunology, 2018, 9, 33.	2.2	71

#	Article	IF	Citations
147	Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors. Frontiers in Immunology, 2018, 9, 797.	2.2	33
148	Changes in the TCRÎ² Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report. Frontiers in Immunology, 2018, 9, 955.	2.2	52
149	Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. Annals of Gastroenterological Surgery, 2018, 2, 289-303.	1.2	35
150	Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment. Biomedicines, 2018, 6, 26.	1.4	16
151	Toward innovative combinational immunotherapy: A systems biology perspective. Cancer Treatment Reviews, 2018, 68, 1-8.	3.4	13
152	Liquid biomarkers in melanoma: detection and discovery. Molecular Cancer, 2018, 17, 8.	7.9	74
153	Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. Experimental and Molecular Medicine, 2018, 50, 1-13.	3.2	152
154	Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discovery, 2018, 8, 1069-1086.	7.7	2,128
155	Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature, 2018, 560, 382-386.	13.7	1,836
156	Checkpoint blockadeâ€based immunotherapy in the context of tumor microenvironment: Opportunities and challenges. Cancer Medicine, 2018, 7, 4517-4529.	1.3	34
157	Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. Oral Oncology, 2018, 85, 29-34.	0.8	15
158	Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors. Cancer Management and Research, 2018, Volume 10, 2475-2488.	0.9	22
159	Drug response to PD-1/PD-L1 blockade: based on biomarkers. OncoTargets and Therapy, 2018, Volume 11, 4673-4683.	1.0	55
160	Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer. Frontiers in Immunology, 2018, 9, 1613.	2.2	83
161	Increased Tim-3+ T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients. Cancer Immunology, Immunotherapy, 2018, 67, 1673-1683.	2.0	42
162	Immunobiology of theÂMelanoma Microenvironment. , 2018, , 133-142.		0
163	Is immune checkpoint inhibition part of standard therapy for stage III nonâ€small cell lung cancer?. Cancer, 2018, 124, 2878-2880.	2.0	0
164	Non-conventional Inhibitory CD4+Foxp3â^'PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer Cell, 2018, 33, 1017-1032.e7.	7.7	112

#	Article	IF	Citations
165	Costâ€effectiveness analysis of imaging strategy for an intensive followâ€up of patients with American Joint Committee on Cancer stage <scp>IIB</scp> , <scp>IIC</scp> and <scp>III</scp> malignant melanoma. British Journal of Dermatology, 2019, 180, 1190-1197.	1.4	23
166	Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 485-495.	1.4	3
167	Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma. Clinical Cancer Research, 2019, 25, 6511-6523.	3.2	62
168	Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. Cell, 2019, 178, 933-948.e14.	13.5	301
169	Extensive exploration of T cell heterogeneity in cancers by single cell sequencing. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 410-418.	0.7	3
170	The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatmentâ€"Review. Frontiers in Immunology, 2019, 10, 2043.	2.2	7
171	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 480-490.	4.2	57
172	PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors. , 2019, 7, 217.		47
173	Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer. , 2019, 7, 218.		64
174	Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade. PLoS ONE, 2019, 14, e0221301.	1.1	16
175	Pseudoprogression: an indicator for cure in combined immunotherapy?. Immunotherapy, 2019, 11, 1087-1093.	1.0	6
176	Antitumor T-cell Homeostatic Activation Is Uncoupled from Homeostatic Inhibition by Checkpoint Blockade. Cancer Discovery, 2019, 9, 1520-1537.	7.7	12
177	PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nature Immunology, 2019, 20, 1231-1243.	7.0	217
178	Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory. OncoImmunology, 2019, 8, e1625687.	2.1	9
179	Relative tumor volume is a better independent prognostic factor in esophageal squamous cell carcinoma. Medicine (United States), 2019, 98, e14963.	0.4	5
180	Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma. Cancer Immunology Research, 2019, 7, 1224-1229.	1.6	26
181	PD-1 aborts the activation trajectory of autoreactive CD8+ T cells to prohibit their acquisition of effector functions. Journal of Autoimmunity, 2019, 105, 102296.	3.0	12
182	The Yin and Yang of Cytoreductive SBRT in Oligometastases and Beyond. Frontiers in Oncology, 2019, 9, 706.	1.3	8

#	Article	IF	Citations
183	T cell receptorâ€based cancer immunotherapy: Emerging efficacy and pathways of resistance. Immunological Reviews, 2019, 290, 127-147.	2.8	180
184	Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer. British Journal of Cancer, 2019, 121, 405-416.	2.9	63
185	Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma. Oncologist, 2019, 24, e1197-e1211.	1.9	15
186	CD163+ immune cell infiltrates and presence of CD54+ microvessels are prognostic markers for patients with embryonal rhabdomyosarcoma. Scientific Reports, 2019, 9, 9211.	1.6	38
187	TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature, 2019, 571, 211-218.	13.7	934
188	Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms. Cancer Discovery, 2019, 9, 1192-1207.	7.7	65
189	Correlates of response and outcomes with talimogene laherperpvec. Journal of Surgical Oncology, 2019, 120, 558-564.	0.8	17
190	Beyond Palliation: The Rationale for Metastasis-Directed Therapy for Metastatic Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 1510-1512.	0.5	5
191	Neutrophilâ€“toâ€“lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors. Anticancer Research, 2019, 39, 5675-5682.	0.5	30
192	Diagnostic accuracy of imaging studies for initial staging of T2b to T4b melanoma patients: A cross-sectional study. Journal of the American Academy of Dermatology, 2019, 81, 1330-1338.	0.6	10
193	NK Cell-Fc Receptors Advance Tumor Immunotherapy. Journal of Clinical Medicine, 2019, 8, 1667.	1.0	17
194	TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8ÂT Cell-Fate Decision. Immunity, 2019, 51, 840-855.e5.	6.6	409
195	Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm. Journal of Translational Medicine, 2019, 17, 338.	1.8	16
196	Common gamma chain cytokines and CD8 T cells in cancer. Seminars in Immunology, 2019, 42, 101307.	2.7	25
197	Applications of biomarkers for different purposes in drug development. , 2019, , 11-40.		1
198	Alterations in composition of immune cells and impairment of anti-tumor immune response in aged oral cancer-bearing mice. Oral Oncology, 2019, 99, 104462.	0.8	11
199	Immune regulation and cytotoxic T cell activation of IL-10 agonists â€“ Preclinical and clinical experience. Seminars in Immunology, 2019, 44, 101325.	2.7	30
200	Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies. Nature Communications, 2019, 10, 5041.	5.8	31

#	Article	IF	Citations
201	Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga. Trends in Cancer, 2019, 5, 779-788.	3.8	22
202	Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade. Journal of Clinical Oncology, 2019, 37, 3546-3555.	0.8	78
203	Heterogenous responses to nivolumab in a single metastatic nodule in hepatocellular carcinoma: role of salvage surgery. Hepatobiliary Surgery and Nutrition, 2019, 8, 569-571.	0.7	5
204	Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma. EBioMedicine, 2019, 49, 96-105.	2.7	47
205	Comparisons between tumor burden and other prognostic factors that influence survival of patients with nonâ€small cell lung cancer treated with immune checkpoint inhibitors. Thoracic Cancer, 2019, 10, 2259-2266.	0.8	18
206	Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. Cancer Cell, 2019, 36, 471-482.	7.7	280
207	Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematology,the, 2019, 6, e480-e488.	2.2	103
208	PD-1+ TIGIT+ CD8+ T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 2041-2054.	2.0	72
209	Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer. , 2019, 7, 302.		72
210	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. JNCI Cancer Spectrum, 2019, 3, pkz071.	1.4	4
212	Combination antiâ€“CTLA-4 plus antiâ€“PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22699-22709.	3.3	226
213	Novel Biomarkers for Personalized Cancer Immunotherapy. Cancers, 2019, 11, 1223.	1.7	36
214	Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies. , 2019, 7, 225.		16
215	Tumor-reprogrammed resident T cells resist radiation to control tumors. Nature Communications, 2019, 10, 3959.	5.8	151
216	Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. , 2019, 7, 249.		61
217	ASO Author Reflections: What Role Do Surgeons Play in the Era of Effective Systemic Therapy for Melanoma?. Annals of Surgical Oncology, 2019, 26, 4619-4620.	0.7	2
218	Paradox-driven adventures in the development of cancer immunology and immunotherapy. Genes and Diseases, 2019, 6, 224-231.	1.5	3
219	Role of CXCR3 signaling in response to anti-PD-1 therapy. EBioMedicine, 2019, 48, 169-177.	2.7	37

#	Article	IF	Citations
220	The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. Journal of Clinical Medicine, 2019, 8, 1534.	1.0	41
221	Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation With Th1 Immune Responses. Frontiers in Immunology, 2019, 10, 2121.	2.2	35
222	A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors . Lung Cancer: Targets and Therapy, 2019, Volume 10, 95-105.	1.3	3
223	Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nature Medicine, 2019, 25, 1549-1559.	15.2	147
224	Trends and Challenges in Tumor Anti-Angiogenic Therapies. Cells, 2019, 8, 1102.	1.8	150
225	Radiation Therapy and Immune Modulation. Hematology/Oncology Clinics of North America, 2019, 33, 233-248.	0.9	6
226	Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer. Medical Sciences (Basel, Switzerland), 2019, 7, 14.	1.3	33
227	Is There a Positive Side to T Cell Exhaustion?. Frontiers in Immunology, 2019, 10, 111.	2.2	32
228	Selectively Potentiating Hypoxia Levels by Combretastatin A4 Nanomedicine: Toward Highly Enhanced Hypoxiaâ€Activated Prodrug Tirapazamine Therapy for Metastatic Tumors. Advanced Materials, 2019, 31, e1805955.	11.1	154
229	Antiâ€“PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment. Cancer Research, 2019, 79, 1493-1506.	0.4	118
230	CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Annual Review of Immunology, 2019, 37, 457-495.	9.5	1,143
231	Clonal Deletion of Tumor-Specific T Cells by Interferon-Î³ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. Immunity, 2019, 50, 477-492.e8.	6.6	93
232	Success of immune checkpoint blockade therapies â€“ mechanisms and implications for hepatology. Zeitschrift Fur Gastroenterologie, 2019, 57, 74-86.	0.2	2
233	Clinical chimeric antigen receptorâ€T cell therapy: a new and promising treatment modality for glioblastoma. Clinical and Translational Immunology, 2019, 8, e1050.	1.7	33
234	Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?. Frontiers in Immunology, 2019, 10, 1181.	2.2	20
235	Advances in cancer immunotherapy 2019 â€“ latest trends. Journal of Experimental and Clinical Cancer Research, 2019, 38, 268.	3.5	401
236	Impact of Effective Systemic Therapy on Metastasectomy in Stage IV Melanoma: A Matched-Pair Analysis. Annals of Surgical Oncology, 2019, 26, 4610-4618.	0.7	20
237	Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer. Journal of Experimental Medicine, 2019, 216, 2128-2149.	4.2	160

#	Article	IF	Citations
238	Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?. Annals of Oncology, 2019, 30, 1448-1459.	0.6	146
239	Who will suffer from hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors. Journal of Thoracic Disease, 2019, 11, S1289-S1291.	0.6	6
240	CD45RA+CCR7â^' CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab. , 2019, 7, 149.		44
241	Prognostic value of B cells in cutaneous melanoma. Genome Medicine, 2019, 11, 36.	3.6	81
242	In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model. Royal Society Open Science, 2019, 6, 190366.	1.1	54
243	IL-27 promotes the expansion of self-renewing CD8+ T cells in persistent viral infection. Journal of Experimental Medicine, 2019, 216, 1791-1808.	4.2	45
244	Monitoring Patient Response to Pembrolizumab With Peripheral Blood Exhaustion Marker Profiles. Frontiers in Medicine, 2019, 6, 113.	1.2	25
245	Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. Frontiers in Medicine, 2019, 6, 119.	1.2	145
246	HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications. International Journal of Molecular Sciences, 2019, 20, 2754.	1.8	43
247	Pan-cancer analysis connects tumor matrisome to immune response. Npj Precision Oncology, 2019, 3, 15.	2.3	58
248	Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. Pharmacological Research, 2019, 145, 104258.	3.1	115
249	Current Status of Immunotherapies for Treating Pancreatic Cancer. Current Oncology Reports, 2019, 21, 60.	1.8	38
250	Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials. Frontiers in Oncology, 2019, 9, 415.	1.3	114
251	Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models. Cancer Immunology Research, 2019, 7, 963-976.	1.6	36
252	Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. Immunity, 2019, 50, 1498-1512.e5.	6.6	406
253	Phosphoâ€'STAT1 expression as a potential biomarker for antiâ€'PDâ€'1/antiâ€'PDâ€'L1 immunotherapy for breast cancer. International Journal of Oncology, 2019, 54, 2030-2038.	1.4	34
254	Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. Cancer Research, 2019, 79, 3940-3951.	0.4	154
255	Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches. Journal of Pathology, 2019, 249, 151-165.	2.1	80

#	Article	IF	Citations
256	Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRÎ² diversity. Cancer Immunology, Immunotherapy, 2019, 68, 1095-1106.	2.0	5
257	The Discovery of Biomarkers in Cancer Immunotherapy. Computational and Structural Biotechnology Journal, 2019, 17, 484-497.	1.9	31
258	Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges. Precision Clinical Medicine, 2019, 2, 57-70.	1.3	24
259	Immunophenotype of T Cells Expressing Programmed Death-1 and Cytotoxic T Cell Antigen-4 in Early Lung Cancer: Local vs. Systemic Immune Response. Cancers, 2019, 11, 567.	1.7	17
260	PI3Kgamma Inhibitor Attenuates Immunosuppressive Effect of Poly(<scp>l</scp>â€Glutamic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 582	5.6	46
261	Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?. Gynecologic Oncology, 2019, 154, 236-245.	0.6	43
262	Recent progress in nanomaterials for nucleic acid delivery in cancer immunotherapy. Biomaterials Science, 2019, 7, 2640-2651.	2.6	34
263	Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Nonâ€“Small Cell Lung Cancer. Cancer Immunology Research, 2019, 7, 896-909.	1.6	64
264	Rational design of anti-GITR-based combination immunotherapy. Nature Medicine, 2019, 25, 759-766.	15.2	180
265	Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. Trends in Immunology, 2019, 40, 511-523.	2.9	180
266	The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment. Clinical Cancer Research, 2019, 25, 5743-5751.	3.2	129
267	Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions. Frontiers in Immunology, 2019, 10, 910.	2.2	54
268	Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy. Frontiers in Oncology, 2019, 9, 199.	1.3	9
269	Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591983992.	1.4	48
270	How Clinical Flow Cytometry Rebooted Sepsis Immunology. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2019, 95, 431-441.	1.1	33
271	First-Line Therapy for Wild-Type Patients. , 2019, , 87-102.		1
272	Immunological and clinical implications of immune checkpoint blockade in human cancer. Archives of Pharmacal Research, 2019, 42, 567-581.	2.7	17
273	Immune-adjuvant loaded Bi2Se3 nanocage for photothermal-improved PD-L1 checkpoint blockade immune-tumor metastasis therapy. Nano Research, 2019, 12, 1770-1780.	5.8	27

#	Article	IF	Citations
274	The Role of Radiation Oncology in Immuno-Oncology. Oncologist, 2019, 24, S42-S52.	1.9	23
275	PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Oncologist, 2019, 24, S31-S41.	1.9	239
276	Toward Curative Immunomodulation Strategies for Chronic Hepatitis B Virus Infection. ACS Infectious Diseases, 2019, 5, 703-712.	1.8	17
277	Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. Journal of the National Cancer Institute, 2019, 111, 655-663.	3.0	56
278	Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors. Cancer Discovery, 2019, 9, 476-481.	7.7	48
279	An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE). , 2019, 7, 72.		38
280	Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. Immunotherapy, 2019, 11, 515-529.	1.0	17
281	Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Annals of Oncology, 2019, 30, 1104-1113.	0.6	205
282	Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers. Journal of Translational Medicine, 2019, 17, 100.	1.8	28
283	Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?. , 2019, 7, 85.		175
284	Engineering Magnetosomes for High-Performance Cancer Vaccination. ACS Central Science, 2019, 5, 796-807.	5.3	66
285	Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity. Cell, 2019, 177, 556-571.e16.	13.5	405
286	Assisting anti-PD-1 antibody treatment with a liposomal system capable of recruiting immune cells. Nanoscale, 2019, 11, 7996-8011.	2.8	7
287	Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment. Scientific Reports, 2019, 9, 2636.	1.6	38
288	The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment. Lung Cancer, 2019, 130, 159-161.	0.9	31
289	Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. , 2019, 7, 37.		123
290	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nature Medicine, 2019, 25, 477-486.	15.2	932
291	A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nature Medicine, 2019, 25, 454-461.	15.2	466

#	Article	IF	Citations
292	Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies. European Urology Oncology, 2019, 2, 79-87.	2.6	26
293	Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cellular and Molecular Immunology, 2019, 16, 430-441.	4.8	327
294	Live or Let Die: T Cell Survival in Cancer Immunotherapy. Immunity, 2019, 50, 280-282.	6.6	2
295	Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma. Journal of Experimental and Clinical Cancer Research, 2019, 38, 87.	3.5	213
296	Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients. OncoImmunology, 2019, 8, e1564505.	2.1	118
297	A first attempt to establish a definition of oligometastatic non-small cell lung cancer by a European consensus group. Journal of Thoracic Disease, 2019, 11, 5635-5642.	0.6	0
298	Evidence for treatment with anti-PD-1 antibody for thymic cancer: how to identify patients most likely to benefit. Shanghai Chest, 0, 3, 63-63.	0.3	0
299	Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer. Oncologist, 2019, 24, 820-828.	1.9	87
300	Programmed cell death protein 1/programmed death ligand-1 checkpoint blockade meets patient-derived organoids. Annals of Translational Medicine, 2019, 7, S287-S287.	0.7	1
301	Immunotherapy and Radiation. Hematology/Oncology Clinics of North America, 2019, 33, 1057-1069.	0.9	2
302	Cisplatin Facilitates Radiation-Induced Abscopal Effects in Conjunction with PD-1 Checkpoint Blockade Through CXCR3/CXCL10-Mediated T-cell Recruitment. Clinical Cancer Research, 2019, 25, 7243-7255.	3.2	57
303	Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?. , 2019, 7, 325.		111
304	Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors. Seminars in Oncology, 2019, 46, 380-384.	0.8	33
305	Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. Journal of Biomedical Science, 2019, 26, 96.	2.6	26
306	Clinical Correlates of Response to Anti-PD-1â€“based Therapy in Patients With Metastatic Melanoma. Journal of Immunotherapy, 2019, 42, 221-227.	1.2	20
307	Platinum-doublet chemotherapy followed by pembrolizumab therapy for lung cancer with lymphangitis carcinomatosa mimicking interstitial pneumonitis. Medicine (United States), 2019, 98, e16834.	0.4	4
308	Tâ€cell exhaustion in HIV infection. Immunological Reviews, 2019, 292, 149-163.	2.8	217
309	Personal response to immune checkpoint inhibitors of patients with advanced melanoma explained by a computational model of cellular immunity, tumor growth, and drug. PLoS ONE, 2019, 14, e0226869.	1.1	12

#	Article	IF	Citations
310	Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Nonâ€“Small Cell Lung Cancer. Integrative Cancer Therapies, 2019, 18, 153473541989002.	0.8	33
311	Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities. Therapeutic Drug Monitoring, 2019, 41, 142-159.	1.0	9
312	Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review. Melanoma Research, 2019, 29, 453-464.	0.6	26
313	Enforcing the checkpoints. Current Opinion in Endocrinology, Diabetes and Obesity, 2019, 26, 213-218.	1.2	25
314	Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor. Anticancer Research, 2019, 39, 6887-6893.	0.5	27
315	Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers, 2019, 11, 1926.	1.7	27
316	Effect and changes in PDâ€‘1 expression of CD19 CARâ€‘Tï¿½cells from Tï¿½cells highly expressing PDâ€‘1 combined with reducedâ€‘dose PDâ€‘1 inhibitor. Oncology Reports, 2019, 41, 3455-3463.	1.2	15
318	The molecular limitations of biomarker research in bladder cancer. World Journal of Urology, 2019, 37, 837-848.	1.2	31
319	Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Annals of Oncology, 2019, 30, 236-242.	0.6	123
320	Ushering in Integrated T Cell Repertoire Profiling in Cancer. Trends in Cancer, 2019, 5, 85-94.	3.8	19
321	TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 BlockadeIn VitroandIn Vivo. Molecular Cancer Therapeutics, 2019, 18, 632-641.	1.9	39
322	Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nature Reviews Drug Discovery, 2019, 18, 197-218.	21.5	2,005
324	Time to abandon single-site irradiation for inducing abscopal effects. Nature Reviews Clinical Oncology, 2019, 16, 123-135.	12.5	233
325	The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC. Lung Cancer, 2019, 127, 153-163.	0.9	77
326	Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types. Cancer Immunology Research, 2019, 7, 86-99.	1.6	27
327	Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade. Gynecologic Oncology, 2019, 152, 251-258.	0.6	33
328	Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Nonâ€“small Cell Lung Cancer Patients. Clinical Cancer Research, 2019, 25, 2219-2227.	3.2	32
329	IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation. Cancer Immunology Research, 2019, 7, 443-457.	1.6	20

#	Article	IF	Citations
330	An Antitumor Immune Response Is Evoked by Partial-Volume Single-Dose Radiation in 2 Murine Models. International Journal of Radiation Oncology Biology Physics, 2019, 103, 697-708.	0.4	62
331	Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1â^'CD8+ Tumor-Infiltrating T Cells. Immunity, 2019, 50, 181-194.e6.	6.6	424
332	Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma. BMC Cancer, 2019, 19, 68.	1.1	44
333	It Is a Capital Mistake to Theorize Who to Treat with Checkpoint Inhibitors before One Has Data. Trends in Cancer, 2019, 5, 79-82.	3.8	4
334	Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. Gastric Cancer, 2019, 22, 793-802.	2.7	124
335	The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. Clinical Cancer Research, 2019, 25, 2144-2154.	3.2	134
336	A new accident causation model based on information flow and its application in Tianjin Port fire and explosion accident. Reliability Engineering and System Safety, 2019, 182, 73-85.	5.1	40
337	Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer. Seminars in Immunopathology, 2019, 41, 21-30.	2.8	49
338	BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways. OncoImmunology, 2019, 8, e1512456.	2.1	15
339	Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy. Molecular Therapy, 2019, 27, 244-260.	3.7	67
340	Followâ€up of the melanoma patient. Journal of Surgical Oncology, 2019, 119, 262-268.	0.8	12
342	Cancer immunoediting and resistance to T cell-based immunotherapy. Nature Reviews Clinical Oncology, 2019, 16, 151-167.	12.5	1,093
343	Regulatory T cells expressing abundant CTLAâ€4 on the cell surface with a proliferative gene profile are key features of human head and neck cancer. International Journal of Cancer, 2019, 144, 2811-2822.	2.3	35
344	Effect of COPD on Inflammation, Lymphoid Functions and Progression-Free Survival during First-Line Chemotherapy in Advanced Non-small Cell Lung Cancer. Pathology and Oncology Research, 2020, 26, 1117-1128.	0.9	6
345	Cancer Immunology. , 2020, , 84-96.e5.		0
346	Loss of nivolumab binding to T cell PD-1 predicts relapse of Hodgkin lymphoma. International Journal of Hematology, 2020, 111, 475-479.	0.7	4
347	Response of patients with melanoma to immune checkpoint blockadeÂâ€“ insights gleaned from analysis of a new mathematical mechanistic model. Journal of Theoretical Biology, 2020, 485, 110033.	0.8	17
348	Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. Journal of Thoracic Oncology, 2020, 15, 266-273.	0.5	58

#	Article	IF	Citations
349	Lactate Dehydrogenase-to-Lymphocyte Ratio Represents a Powerful Prognostic Tool of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors. Pathology and Oncology Research, 2020, 26, 1319-1324.	0.9	5
350	Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review. Seminars in Cancer Biology, 2020, 64, 93-101.	4.3	135
351	4â€1BB Delineates Distinct Activation Status of Exhausted Tumorâ€Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. Hepatology, 2020, 71, 955-971.	3.6	70
352	Immune-resistant mechanisms in cancer immunotherapy. International Journal of Clinical Oncology, 2020, 25, 810-817.	1.0	39
353	Elite Intratumoral T-cell Clonotypes (The 1%) Effect â€œTrickle-Down Cytotoxicityâ€• Clinical Cancer Research, 2020, 26, 1205-1207.	3.2	1
354	The potential application of PD-1 blockade therapy for early-stage biliary tract cancer. International Immunology, 2020, 32, 273-281.	1.8	10
355	Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies. ACS Nano, 2020, 14, 651-663.	7.3	49
356	A phase 2 clinical trialâ€assessing theâ€efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic tripleâ€negative breast cancer. Cancer, 2020, 126, 850-860.	2.0	116
357	Nanoparticle Conjugation of Ginsenoside Rg3 Inhibits Hepatocellular Carcinoma Development and Metastasis. Small, 2020, 16, e1905233.	5.2	72
358	Targeting innate sensing in the tumor microenvironment to improve immunotherapy. Cellular and Molecular Immunology, 2020, 17, 13-26.	4.8	76
359	Mechanisms of resistance and predictive biomarkers of response to targeted therapies and immunotherapies in metastatic melanoma. Current Opinion in Oncology, 2020, 32, 91-97.	1.1	7
360	Blocking inflammation to improve immunotherapy of advanced cancer. Immunology, 2020, 159, 357-364.	2.0	34
361	Peritoneal Metastases in Colorectal Cancer: Biology and Barriers. Journal of Gastrointestinal Surgery, 2020, 24, 720-727.	0.9	17
362	Promising approaches in cancer immunotherapy. Immunobiology, 2020, 225, 151875.	0.8	49
363	Immune checkpoint blockade and biomarkers of clinical response in nonâ€“small cell lung cancer. Scandinavian Journal of Immunology, 2020, 92, e12980.	1.3	14
364	Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Science Immunology, 2020, 5, .	5.6	148
365	CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. , 2020, 8, e000847.		45
366	Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer. Frontiers in Immunology, 2020, 11, 603157.	2.2	28

#	Article	IF	Citations
367	Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clinical Cancer Research, 2020, 26, 6437-6444.	3.2	43
368	Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab. Frontiers in Immunology, 2020, 11, 579894.	2.2	4
369	Seeing the invisible hand: Underlying effects of COVID-19 on touristsâ€™ behavioral patterns. Journal of Destination Marketing & Management, 2020, 18, 100502.	3.4	99
370	PD1 blockade enhances K⁺channel activity, Ca²⁺signaling, and migratory ability in cytotoxic T lymphocytes of patients with head and neck cancer. , 2020, 8, e000844.		21
371	Machine learning reveals a PD-L1â€“independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context. European Journal of Cancer, 2020, 140, 76-85.	1.3	30
372	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. IScience, 2020, 23, 101580.	1.9	22
373	Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: a systematic review and meta-analysis. OncoImmunology, 2020, 9, 1824646.	2.1	17
374	ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Annals of Oncology, 2020, 31, 1435-1448.	0.6	132
375	Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. , 2020, 8, e000678.		78
376	Cellular and Molecular Mechanisms of CD8+ T Cell Differentiation, Dysfunction and Exhaustion. International Journal of Molecular Sciences, 2020, 21, 7357.	1.8	43
377	Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. Cancer Medicine, 2020, 9, 8650-8661.	1.3	11
378	Stereotactic Body Radiation Therapy to a Splenic Metastasis in Oligoprogressive Non-small Cell Lung Cancer. Advances in Radiation Oncology, 2020, 5, 516-521.	0.6	0
379	Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nature Communications, 2020, 11, 3475.	5.8	341
380	Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science, 2020, 369, .	6.0	1,280
381	Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy. Biomedicine and Pharmacotherapy, 2020, 129, 110457.	2.5	19
382	Shed it, and helpâ€”LAG3 cleavage drives conventional CD4 ⁺ T cells to overcome resistance to PD-1 immunotherapy. Science Immunology, 2020, 5, .	5.6	4
383	Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy. , 2020, 8, e000967.		67
384	Tâ€cell receptor repertoire analysis for the diagnosis and treatment of solid tumor: A methodology and clinical applications. Cancer Communications, 2020, 40, 473-483.	3.7	25

#	Article	IF	Citations
385	Generation of highly activated, antigen-specific tumor-infiltrating CD8 ⁺ T cells induced by a novel T cell-targeted immunotherapy. OncoImmunology, 2020, 9, 1782574.	2.1	2
386	Telomerase and CD4 T Cell Immunity in Cancer. Cancers, 2020, 12, 1687.	1.7	20
387	Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma. Cancers, 2020, 12, 3374.	1.7	27
388	Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy. Frontiers in Immunology, 2020, 11, 584423.	2.2	39
389	Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects. Cancers, 2020, 12, 3456.	1.7	12
390	Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers. Cancers, 2020, 12, 3459.	1.7	11
391	CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer. Nature Communications, 2020, 11, 6119.	5.8	53
392	Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy. Frontiers in Immunology, 2020, 11, 586907.	2.2	40
393	Singleâ€Cell Immune Profiling in Coronary Artery Disease: The Role of Stateâ€ofâ€theâ€Art Immunophenotyping With Mass Cytometry in the Diagnosis of Atherosclerosis. Journal of the American Heart Association, 2020, 9, e017759.	1.6	19
394	Prospective Evaluation of All-lesion Versus Single-lesion Radiotherapy in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors. Frontiers in Oncology, 2020, 10, 576643.	1.3	13
395	Overcoming Immune Evasion in Melanoma. International Journal of Molecular Sciences, 2020, 21, 8984.	1.8	88
396	A phase II, single-centre trial of neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma. Journal of Thoracic Disease, 2020, 12, 6861-6867.	0.6	20
397	Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials. EBioMedicine, 2020, 62, 103040.	2.7	35
398	The Role of Extrapleural Pneumonectomy in Malignant Pleural Mesothelioma. Thoracic Surgery Clinics, 2020, 30, 461-471.	0.4	2
399	PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy. , 2020, 8, e001631.		44
400	Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094237.	1.4	7
401	An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors. , 2020, 8, e000883.		36
402	Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper. British Journal of Cancer, 2020, 123, 874-884.	2.9	15

#	Article	IF	Citations
403	SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. Journal of Hematology and Oncology, 2020, 13, 105.	6.9	73
404	A brief report on combination chemotherapy and antiâ€“programmed death (ligand) 1 treatment in small-cell lung cancer: Did we choose the optimal chemotherapy backbone?. European Journal of Cancer, 2020, 137, 40-44.	1.3	5
405	Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy. Tumori, 2020, 107, 030089162094038.	0.6	8
406	Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study. , 2020, 8, e000645.		54
407	Targeting the immune milieu in gastrointestinal cancers. Journal of Gastroenterology, 2020, 55, 909-926.	2.3	7
408	Radiation Therapy and the In Situ Vaccination Approach. International Journal of Radiation Oncology Biology Physics, 2020, 108, 891-898.	0.4	46
409	Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nature Communications, 2020, 11, 4011.	5.8	198
410	Prediction model for hyperprogressive disease in nonâ€small cell lung cancer treated with immune checkpoint inhibitors. Thoracic Cancer, 2020, 11, 2793-2803.	0.8	18
411	Choice of Nanovaccine Delivery Mode Has Profound Impacts on the Intralymph Node Spatiotemporal Distribution and Immunotherapy Efficacy. Advanced Science, 2020, 7, 2001108.	5.6	21
412	Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. Cell, 2020, 183, 1479-1495.e20.	13.5	449
413	The science and medicine of human immunology. Science, 2020, 369, .	6.0	147
414	The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nature Immunology, 2020, 21, 1346-1358.	7.0	431
415	A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model . OncoTargets and Therapy, 2020, Volume 13, 8109-8124.	1.0	4
416	Palliative Radiofrequency Ablation Accelerates the Residual Tumor Progression Through Increasing Tumor-Infiltrating MDSCs and Reducing T-Cell-Mediated Anti-Tumor Immune Responses in Animal Model. Frontiers in Oncology, 2020, 10, 1308.	1.3	17
417	Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 23721-23729.	3.3	45
418	A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 23684-23694.	3.3	32
419	Chemical Strategies to Boost Cancer Vaccines. Chemical Reviews, 2020, 120, 11420-11478.	23.0	95
420	Microneedles loaded with anti-PD-1â€“cisplatin nanoparticles for synergistic cancer immuno-chemotherapy. Nanoscale, 2020, 12, 18885-18898.	2.8	67

#	Article	IF	Citations
421	Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2020, 108, 17-26.	0.4	18
422	Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Research, 2020, 30, 966-979.	5.7	349
423	Immunotherapy for advanced thyroid cancers â€" rationale, current advances and future strategies. Nature Reviews Endocrinology, 2020, 16, 629-641.	4.3	49
424	A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma. , 2020, 8, e001866.		13
425	Immune Modulation in Lung Cancer: Current Concepts and Future Strategies. Respiration, 2020, 99, 903-929.	1.2	18
426	Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations. Radiation Oncology, 2020, 15, 254.	1.2	62
427	iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and antiâ€“PD-1 therapy. Science Translational Medicine, 2020, 12, .	5.8	133
428	Progress and applications of mass cytometry in sketching immune landscapes. Clinical and Translational Medicine, 2020, 10, e206.	1.7	27
429	Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses. Frontiers in Immunology, 2020, 11, 587014.	2.2	56
430	Heterogeneity of exhausted T cells in the tumor microenvironment is linked to patient survival following resection in hepatocellular carcinoma. OncoImmunology, 2020, 9, 1746573.	2.1	21
431	Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches. Frontiers in Immunology, 2020, 11, 849.	2.2	79
432	Low-frequency ultrasound-mediated cytokine transfection enhances T cell recruitment at local and distant tumor sites. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12674-12685.	3.3	61
433	Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. Clinical Cancer Research, 2020, 26, 2827-2837.	3.2	86
434	Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. Cancer Discovery, 2020, 10, 1121-1128.	7.7	206
435	Trials and Tribulations of Radio-Immuno-Oncology. Seminars in Radiation Oncology, 2020, 30, 108-112.	1.0	3
436	Combining Radiation with Immunotherapy: The University of Pennsylvania Experience. Seminars in Radiation Oncology, 2020, 30, 173-180.	1.0	6
437	18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. Cancer Imaging, 2020, 20, 36.	1.2	46
438	The Landmark Series: Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients â€" A Potential Paradigm Shift in Management. Annals of Surgical Oncology, 2020, 27, 2188-2200.	0.7	4

#	Article	IF	Citations
439	Immunotherapy and Response Assessment in Malignant Glioma. Topics in Magnetic Resonance Imaging, 2020, 29, 95-102.	0.7	5
441	Facing SARS-CoV-2 outbreak in immunotherapy era. Future Oncology, 2020, 16, 1475-1485.	1.1	9
442	Killing the â€œBADâ€• Challenges for immunotherapy in pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188384.	3.3	14
443	Accelerating the Development of Personalized Cancer Immunotherapy by Integrating Molecular Patientsâ€™ Profiles with Dynamic Mathematical Models. Clinical Pharmacology and Therapeutics, 2020, 108, 515-527.	2.3	14
444	Genetically modified immune cells targeting tumor antigens. , 2020, 214, 107603.		17
445	Circulating immune cell phenotype dynamics reflect the strength of tumorâ€“immune cell interactions in patients during immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16072-16082.	3.3	60
446	Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. Annals of Surgical Oncology, 2020, 27, 4122-4130.	0.7	7
447	Targeting Nuclear LSD1 to Reprogram Cancer Cells and Reinvigorate Exhausted T Cells via a Novel LSD1-EOMES Switch. Frontiers in Immunology, 2020, 11, 1228.	2.2	49
448	Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 4814-4822.	3.2	82
449	A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer. Oncologist, 2020, 25, 1013-e1824.	1.9	40
450	Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28. Frontiers in Oncology, 2020, 10, 760.	1.3	33
451	Immune Checkpoint Markers in Neuroendocrine Carcinoma of the Digestive System. Frontiers in Oncology, 2020, 10, 132.	1.3	19
452	Regulation of Cancer Immune Checkpoints. Advances in Experimental Medicine and Biology, 2020, , .	0.8	7
453	Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma. BMC Cancer, 2020, 20, 229.	1.1	30
454	Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients. Frontiers in Immunology, 2020, 11, 372.	2.2	20
455	Lactate dehydrogenase: a marker of diminished antitumor immunity. OncoImmunology, 2020, 9, 1731942.	2.1	107
456	Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation. Clinical Immunology, 2020, 213, 108377.	1.4	44
457	Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors. Frontiers in Immunology, 2020, 11, 490.	2.2	38

#	Article	IF	Citations
458	Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer. Frontiers in Immunology, 2020, 11, 366.	2.2	21
459	A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation. Cancer Immunology Research, 2020, 8, 596-608.	1.6	28
460	Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 8022-8031.	3.3	84
461	A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma. Clinical Cancer Research, 2020, 26, 3193-3201.	3.2	27
462	Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer. Genome Medicine, 2020, 12, 22.	3.6	98
463	Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2020, 69, 2599-2611.	2.0	21
464	The Role of Neoadjuvant Therapy in Melanoma. Current Oncology Reports, 2020, 22, 80.	1.8	8
465	Cancer and HIV-1 Infection: Patterns of Chronic Antigen Exposure. Frontiers in Immunology, 2020, 11, 1350.	2.2	13
466	Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer. OncoImmunology, 2020, 9, 1773205.	2.1	3
467	CD8⁺CD57⁺ T cells exhibit distinct features in human non-small cell lung cancer. , 2020, 8, e000639.		24
468	Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection. Frontiers in Oncology, 2020, 10, 1043.	1.3	29
469	Identification of FABP5 as an immunometabolic marker in human hepatocellular carcinoma. , 2020, 8, e000501.		29
470	TOX is expressed by exhausted and polyfunctional human effector memory CD8 ⁺ T cells. Science Immunology, 2020, 5, .	5.6	125
471	Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review. Frontiers in Immunology, 2020, 11, 1036.	2.2	10
472	A possible asymmetry at the checkpoint. Translational Oncology, 2020, 13, 100821.	1.7	0
473	Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, , .	0.8	3
474	PD-1+ stemlike CD8 T cells are resident in lymphoid tissues during persistent LCMV infection. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 4292-4299.	3.3	85
475	Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-Î²B inhibitor for antitumor immunotherapy. Science Advances, 2020, 6, eaay7785.	4.7	95

#	Article	IF	Citations
476	Use of Mass Cytometry to Profile Human T Cell Exhaustion. Frontiers in Immunology, 2019, 10, 3039.	2.2	37
477	Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy. Nature Cancer, 2020, 1, 210-221.	5.7	138
478	Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, e405-e414.	1.1	21
479	Critical role of PD-L1 expression on non-tumor cells rather than on tumor cells for effective anti-PD-L1 immunotherapy in a transplantable mouse hematopoietic tumor model. Cancer Immunology, Immunotherapy, 2020, 69, 1001-1014.	2.0	7
480	Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Nonâ€“Small-Cell Lung Cancer and High PD-L1 Tumor Expression. Clinical Lung Cancer, 2020, 21, e366-e379.	1.1	26
481	Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma. Auris Nasus Larynx, 2020, 47, 650-657.	0.5	16
482	Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma. Nature Medicine, 2020, 26, 193-199.	15.2	211
483	Tracking early response to immunotherapy. Nature Cancer, 2020, 1, 160-162.	5.7	9
484	Radiotherapy and Immunotherapy for Cancer: From â€œSystemicâ€•to â€œMultisiteâ€• Clinical Cancer Research, 2020, 26, 2777-2782.	3.2	103
485	Very rapid cloning, expression and identifying specificity of T-cell receptors for T-cell engineering. PLoS ONE, 2020, 15, e0228112.	1.1	6
486	Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIBâ€“IV M1c melanoma patients. Cancer Immunology, Immunotherapy, 2020, 69, 759-769.	2.0	20
487	Prognostic Biomarkers for Melanoma Immunotherapy. Current Oncology Reports, 2020, 22, 25.	1.8	13
488	VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours. Nature, 2020, 577, 689-694.	13.7	321
489	Monthly changes in serum levels of S100B protein as a predictor of metastasis development in highâ€•risk melanoma patients. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1482-1488.	1.3	9
490	Enrichment of melanoma-associated T cells in 6-thioguanine-resistant T cells from metastatic melanoma patients. Melanoma Research, 2020, 30, 52-61.	0.6	2
491	TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Nonâ€“Small Cell Lung Cancer. Cancer Immunology Research, 2020, 8, 146-154.	1.6	166
492	Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. International Journal of Molecular Sciences, 2020, 21, 556.	1.8	21
493	Molecular Imaging for Cancer Immunotherapy: Seeing Is Believing. Bioconjugate Chemistry, 2020, 31, 404-415.	1.8	31

#	Article	IF	Citations
494	Biomarkers for Melanoma. , 2020, , 73-104.		0
495	Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination. International Journal of Cancer, 2020, 147, 1509-1518.	2.3	44
496	Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response. Journal of Clinical Medicine, 2020, 9, 286.	1.0	50
497	Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials. Immunity, 2020, 52, 36-54.	6.6	127
498	Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. OncoImmunology, 2020, 9, 1703449.	2.1	156
499	Does progress achieved in the treatment of patients with metastatic nonâ€smallâ€cell lung cancer reach the elderly population? A cohort study from a cancer centre from Eastern Switzerland. European Journal of Cancer Care, 2020, 29, e13206.	0.7	3
500	Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science, 2020, 369, .	6.0	351
501	Ex Vivo Exposure of Human Melanoma Tissue to Cold Physical Plasma Elicits Apoptosis and Modulates Inflammation. Applied Sciences (Switzerland), 2020, 10, 1971.	1.3	23
502	Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature. Cancer Immunology, Immunotherapy, 2020, 69, 1823-1832.	2.0	19
503	Unravelling the heterogeneity and dynamic relationships of tumorâ€infiltrating T cells by singleâ€cell RNA sequencing analysis. Journal of Leukocyte Biology, 2020, 107, 917-932.	1.5	21
504	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 1327-1337.	3.2	90
505	Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer. International Journal of Clinical Oncology, 2020, 25, 1270-1277.	1.0	12
506	Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Annals of Oncology, 2020, 31, 525-531.	0.6	188
507	Acquired Resistance to Immune Checkpoint Inhibitors. Cancer Cell, 2020, 37, 443-455.	7.7	444
508	Checkpoint inhibitors for the treatment of JC virus-related progressive multifocal leukoencephalopathy. Current Opinion in Virology, 2020, 40, 19-27.	2.6	14
509	Learning from clinical trials of neoadjuvant checkpoint blockade. Nature Medicine, 2020, 26, 475-484.	15.2	107
510	Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin. International Journal of Gynecological Cancer, 2020, 30, 409-423.	1.2	15
511	Master protocols in immuno-oncology: do novel drugs deserve novel designs?. , 2020, 8, e000475.		17

#	Article	IF	Citations
512	The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer. Frontiers in Immunology, 2020, 11, 604.	2.2	51
513	Identification of Potential Biomarkers for Anti-PD-1 Therapy in Melanoma by Weighted Correlation Network Analysis. Genes, 2020, 11, 435.	1.0	14
514	Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma. Journal of Molecular Medicine, 2020, 98, 805-818.	1.7	19
515	Prediction of Immune checkpoint inhibitors benefit from routinely measurable peripheral blood parameters. Chinese Clinical Oncology, 2020, 9, 19-19.	0.4	6
516	Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting. Clinical Cancer Research, 2020, 26, 2087-2095.	3.2	35
517	Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer. Oncologist, 2020, 25, 515-522.	1.9	7
518	Molecular T-Cell Repertoire Analysis as Source of Prognostic and Predictive Biomarkers for Checkpoint Blockade Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 2378.	1.8	48
519	Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies. International Journal of Molecular Sciences, 2020, 21, 2411.	1.8	28
520	PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-15. Cellular and Molecular Immunology, 2021, 18, 385-397.	4.8	37
521	Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenocarcinomas harboring EGFR mutations. Oncogene, 2021, 40, 355-368.	2.6	115
522	Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer. Cancer Discovery, 2021, 11, 362-383.	7.7	50
523	Biomarkers for predicting the outcome of various cancer immunotherapies. Critical Reviews in Oncology/Hematology, 2021, 157, 103161.	2.0	10
524	Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner. International Immunology, 2021, 33, 39-48.	1.8	4
525	Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. Blood, 2021, 137, 216-231.	0.6	40
526	Targeting <scp>CTLA</scp>â€4 in cancer: Is it the ideal companion for <scp>PD</scp>â€1 blockade immunotherapy combinations?. International Journal of Cancer, 2021, 149, 31-41.	2.3	23
527	Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial. Clinical Cancer Research, 2021, 27, 1267-1277.	3.2	21
528	Tumorâ€derived exosomes in the PDâ€1/PDâ€L1 axis: Significant regulators as well as promising clinical targets. Journal of Cellular Physiology, 2021, 236, 4138-4151.	2.0	17
529	Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience. Clinical and Translational Oncology, 2021, 23, 1245-1252.	1.2	21

#	Article	IF	Citations
530	Dynamic changes in circulating PD-1+CD8+ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer. European Journal of Cancer, 2021, 143, 113-126.	1.3	30
531	Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annual Review of Pathology: Mechanisms of Disease, 2021, 16, 223-249.	9.6	956
532	Proposing synchronous oligometastatic nonâ€“smallâ€cell lung cancer based on progression after firstâ€line systemic therapy. Cancer Science, 2021, 112, 359-368.	1.7	10
533	CAR T-cells profiling in carcinogenesis and tumorigenesis: An overview of CAR T-cells cancer therapy. International Immunopharmacology, 2021, 90, 107201.	1.7	9
534	Immunogenic-cell-killing and immunosuppression-inhibiting nanomedicine. Bioactive Materials, 2021, 6, 1513-1527.	8.6	63
535	Biology-guided radiotherapy: redefining the role of radiotherapy in metastatic cancer. British Journal of Radiology, 2021, 94, 20200873.	1.0	44
536	PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies. Trends in Molecular Medicine, 2021, 27, 207-219.	3.5	23
537	Parallels Between the Antiviral State and the Irradiated State. Journal of the National Cancer Institute, 2021, 113, 969-979.	3.0	4
538	Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma. Cancer Immunology Research, 2021, 9, 136-146.	1.6	12
539	Ternary Regulation of Tumor Microenvironment by Heparanaseâ€Sensitive Micelleâ€Loaded Monocytes Improves Chemoâ€Immunotherapy of Metastatic Breast Cancer. Advanced Functional Materials, 2021, 31, 2007402.	7.8	19
540	Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188463.	3.3	16
541	Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients. Cancer Immunology, Immunotherapy, 2021, 70, 563-568.	2.0	3
542	Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment. Breast Cancer Research and Treatment, 2021, 185, 85-94.	1.1	15
543	Reinvigorating exhausted CD8⁺ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. Medicinal Research Reviews, 2021, 41, 156-201.	5.0	56
544	Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101. Theranostics, 2021, 11, 5955-5969.	4.6	23
545	T Cells Expanded from PD-1+ Peripheral Blood Lymphocytes Share More Clones with Paired Tumor-Infiltrating Lymphocytes. Cancer Research, 2021, 81, 2184-2194.	0.4	18
546	Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response. Journal of Clinical Investigation, 2021, 131, .	3.9	48
547	Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients. OncoImmunology, 2021, 10, 1926762.	2.1	32

#	Article	IF	Citations
548	The Present and Future of Screening in Breast Cancer Prevention. , 2021, , 163-173.		0
549	Immunopathogenesis of Immune-Related Adverse Events from Cancer Immunotherapy. , 2021, , 49-68.		0
550	(Oligo)metastasis as a Spectrum of Disease. Cancer Research, 2021, 81, 2577-2583.	0.4	22
551	Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nature Communications, 2021, 12, 346.	5.8	107
552	Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment. Human Vaccines and Immunotherapeutics, 2021, 17, 1555-1567.	1.4	17
553	The Impact of Priming Effect of Immune Checkpoint Inhibitor Therapy for Advanced Stage Non-Small Cell Lung Cancer: A Meta-Epidemiological Study. SSRN Electronic Journal, 0, , .	0.4	0
554	The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy. BMC Cancer, 2021, 21, 19.	1.1	24
555	CD155-Prognostic and Immunotherapeutic Implications Based on Multiple Analyses of Databases Across 33 Human Cancers. Technology in Cancer Research and Treatment, 2021, 20, 153303382098008.	0.8	4
556	Oral administration of Bifidobacterium breve promotes antitumor efficacy via dendritic cells-derived interleukin 12. OncoImmunology, 2021, 10, 1868122.	2.1	24
557	Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1. , 2021, 9, e001698.		78
558	Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC. Theranostics, 2021, 11, 7092-7109.	4.6	11
559	A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909). Annals of Translational Medicine, 2021, 9, 73-73.	0.7	32
560	PD-1 Blockade Aggravates Epsteinâ€“Barr Virus+ Post-Transplant Lymphoproliferative Disorder in Humanized Mice Resulting in Central Nervous System Involvement and CD4+ T Cell Dysregulations. Frontiers in Oncology, 2020, 10, 614876.	1.3	19
561	Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies. OncoImmunology, 2021, 10, 1909296.	2.1	13
562	A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	11.4	8
563	Baseline lesion number as an efficacy predictive and independent prognostic factor and its joint utility with TMB for PD-1 inhibitor treatment in advanced gastric cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592198899.	1.4	17
564	Peripheral CD4+ T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer. Science China Life Sciences, 2021, 64, 1590-1601.	2.3	9
565	Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts. , 2021, 9, e001615.		18

#	Article	IF	Citations
566	Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors. , 2021, 9, e001845.		36
567	Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy. Frontiers in Immunology, 2020, 11, 622509.	2.2	148
568	Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple Myeloma. Frontiers in Immunology, 2021, 12, 618610.	2.2	7
569	Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. Nature Communications, 2021, 12, 935.	5.8	56
570	A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2021, 27, 2470-2480.	3.2	51
571	Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy. Nature Communications, 2021, 12, 951.	5.8	50
572	Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity. Journal of Experimental and Clinical Cancer Research, 2021, 40, 74.	3.5	19
573	Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab. Scientific Reports, 2021, 11, 2741.	1.6	16
574	Chromatin accessibility of circulating CD8+ T cells predicts treatment response to PD-1 blockade in patients with gastric cancer. Nature Communications, 2021, 12, 975.	5.8	26
575	Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes. Frontiers in Immunology, 2020, 11, 629722.	2.2	75
576	Combined antiâ€PDâ€1 and antiâ€CTLAâ€4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. European Journal of Immunology, 2021, 51, 544-556.	1.6	71
577	Persistence of self-reactive CD8+ T cells in the CNS requires TOX-dependent chromatin remodeling. Nature Communications, 2021, 12, 1009.	5.8	19
578	Predictive lifestyle markers for efficacy of cancer immune checkpoint inhibitors: a commentary. Future Oncology, 2021, 17, 363-369.	1.1	1
579	Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy. Journal of Immunology Research, 2021, 2021, 1-18.	0.9	29
580	Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy. Nature Cancer, 2021, 2, 300-311.	5.7	70
581	Dual-Sensitive PEG-Sheddable Nanodrug Hierarchically Incorporating PD-L1 Antibody and Zinc Phthalocyanine for Improved Immuno-Photodynamic Therapy. ACS Applied Materials & Interfaces, 2021, 13, 12845-12856.	4.0	35
582	Transient Depletion of CD4+ Cells Induces Remodeling of the TCR Repertoire in Gastrointestinal Cancer. Cancer Immunology Research, 2021, 9, 624-636.	1.6	13
583	Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma. World Journal of Gastroenterology, 2021, 27, 919-927.	1.4	14

#	Article	IF	Citations
584	Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment. Journal of Experimental Medicine, 2021, 218, .	4.2	74
585	Memory T-Cell Heterogeneity and Terminology. Cold Spring Harbor Perspectives in Biology, 2021, 13, a037929.	2.3	26
586	Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes. Frontiers in Immunology, 2021, 12, 607282.	2.2	19
588	TNF in the era of immune checkpoint inhibitors: friend or foe?. Nature Reviews Rheumatology, 2021, 17, 213-223.	3.5	77
589	Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors. Journal of Clinical Medicine, 2021, 10, 1251.	1.0	21
590	Melanoma-reactive T cells take up residence. Nature Cancer, 2021, 2, 253-255.	5.7	1
591	A New Method for Optimizing Sepsis Therapy by Nivolumab and Meropenem Combination: Importance of Early Intervention and CTL Reinvigoration Rate as a Response Marker. Frontiers in Immunology, 2021, 12, 616881.	2.2	3
592	Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy. Nature Communications, 2021, 12, 1669.	5.8	48
593	InÂvivo CD8+ TÂcell CRISPR screening reveals control by Fli1 in infection and cancer. Cell, 2021, 184, 1262-1280.e22.	13.5	107
594	Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases. Cancer Biology and Therapy, 2021, 22, 175-183.	1.5	13
595	CD8⁺T-Cell Memory: The Why, the When, and the How. Cold Spring Harbor Perspectives in Biology, 2021, 13, a038661.	2.3	7
597	Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers. Frontiers in Oncology, 2021, 11, 638873.	1.3	23
598	T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. Nature Communications, 2021, 12, 1402.	5.8	85
599	Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade. Frontiers in Oncology, 2021, 11, 617335.	1.3	49
600	The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy. Aids, 2021, 35, 1631-1636.	1.0	16
601	Radiotherapy in the Era of ImmunotherapyÂWith a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?. Frontiers in Oncology, 2021, 11, 662236.	1.3	19
603	Malignant Pleural Effusionsâ€"A Window Into Local Anti-Tumor T Cell Immunity?. Frontiers in Oncology, 2021, 11, 672747.	1.3	9
604	Systemic immunity in cancer. Nature Reviews Cancer, 2021, 21, 345-359.	12.8	605

#	Article	IF	Citations
605	STARTRAC analyses of scRNAseq data from tumor models reveal T cell dynamics and therapeutic targets. Journal of Experimental Medicine, 2021, 218, .	4.2	15
606	Epigenomics and immunotherapeutic advances in pediatric brain tumors. Npj Precision Oncology, 2021, 5, 34.	2.3	9
607	Identification of 15 lncRNAs Signature for Predicting Survival Benefit of Advanced Melanoma Patients Treated with Anti-PD-1 Monotherapy. Cells, 2021, 10, 977.	1.8	25
608	Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model. Molecular Cancer Research, 2021, 19, 1422-1436.	1.5	3
609	Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?. , 2021, 9, e002038.		124
610	Abscopal effect after palliative five-fraction radiation therapy on bone and lymph node metastases from luminal B breast cancer: a case report and clinical implications for palliative radiation therapy. Radiation Oncology Journal, 2021, 39, 139-144.	0.7	6
612	Tenascinâ€€ immobilizes infiltrating T lymphocytes through CXCL12 promoting breast cancer progression. EMBO Molecular Medicine, 2021, 13, e13270.	3.3	27
613	Combination radiation and immunotherapy in gynecologic malignanciesâ€”a comprehensive review. Translational Cancer Research, 2021, 10, 2609-2619.	0.4	4
614	Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvantÂtherapy. Annals of Oncology, 2021, 32, 590-599.	0.6	91
615	The tumor microenvironment shapes the molecular characteristics of exhausted CD8+ T cells. Cancer Letters, 2021, 506, 55-66.	3.2	20
616	Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 TÂcells. Cell Reports, 2021, 35, 109120.	2.9	60
618	Emerging concepts in PD-1 checkpoint biology. Seminars in Immunology, 2021, 52, 101480.	2.7	84
619	Melanoma Cell State-Specific Responses to TNFÎ±. Biomedicines, 2021, 9, 605.	1.4	1
620	Pembrolizumab-induced hypothyreosis and subcutaneous bleeding. Vnitrni Lekarstvi, 2021, 67, 175-179.	0.1	2
621	Adoptive Î³Î´T-cell transfer alone or combined with chemotherapy for the treatment of advanced esophageal cancer. Cytotherapy, 2021, 23, 423-432.	0.3	3
622	The Potential of Aptamer-Mediated Liquid Biopsy for Early Detection of Cancer. International Journal of Molecular Sciences, 2021, 22, 5601.	1.8	22
623	Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome. Clinical and Translational Oncology, 2021, 23, 2237-2252.	1.2	7
624	Induced pluripotent stem cell-derived, genetically engineered myeloid cells as unlimited cell source for dendritic cell-related cancer immunotherapy. Journal of Immunology and Regenerative Medicine, 2021, 12, 100042.	0.2	0

#	Article	IF	Citations
625	PD-L1 as a prognostic and predictive biomarker in neuroendocrine tumors of the lung: state of the art and future perspectives. Minerva Respiratory Medicine, 2021, 60, .	0.1	4
626	The therapeutic landscape of hepatocellular carcinoma. Med, 2021, 2, 505-552.	2.2	20
627	Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. , 2021, 9, e002350.		11
628	Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation. Cancer Discovery, 2021, 11, 2564-2581.	7.7	58
629	Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures. Cancers, 2021, 13, 2630.	1.7	3
630	Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in nonâ€“small cell lung cancers. Science Advances, 2021, 7, .	4.7	12
631	Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection. Npj Breast Cancer, 2021, 7, 59.	2.3	5
632	Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 346-359.	4.2	70
633	PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. International Journal of Molecular Sciences, 2021, 22, 5123.	1.8	61
634	Advances in siRNA delivery strategies for the treatment of MDR cancer. Life Sciences, 2021, 274, 119337.	2.0	21
635	Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors. Expert Opinion on Biological Therapy, 2021, 21, 1575-1590.	1.4	7
636	Beyond the single average tumor: Understanding IO combinations using a clinical QSP model that incorporates heterogeneity in patient response. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 684-695.	1.3	7
637	Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model. Cancers, 2021, 13, 2782.	1.7	21
638	Complete response in a patient with advanced melanoma following antiâ€PDâ€1 therapy is associated with a high frequency of melanomaâ€infiltrating CXCR3 ⁺ resident memory CD8 ⁺ T cells and multiple chemokine pathways. British Journal of Dermatology, 2021, 185, 663-666.	1.4	1
639	Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma. Hepatology, 2021, 74, 483-490.	3.6	48
640	Cancer immunotherapy: itâ€™s time to better predict patientsâ€™ response. British Journal of Cancer, 2021, 125, 927-938.	2.9	63
641	Follicular helper-T cells restore CD8⁺-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy. , 2021, 9, e002157.		63
642	Routine PET-CT scans provide early and accurate recurrence detection in asymptomatic stage IIB-III melanoma patients. European Journal of Surgical Oncology, 2021, 47, 3020-3027.	0.5	7

#	Article	IF	Citations
643	Endothelin Inhibition Potentiates Cancer Immunotherapy Revealing Mechanical Biomarkers Predictive of Response. Advanced Therapeutics, 2021, 4, 2000289.	1.6	8
644	Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 5510-5518.	3.2	23
645	Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced nonâ€“small cell lung cancer treated with first-line pembrolizumab. European Journal of Cancer, 2021, 150, 99-107.	1.3	36
646	Cancer Immunotherapies: From Efficacy to Resistance Mechanisms â€“ Not Only Checkpoint Matters. Frontiers in Immunology, 2021, 12, 690112.	2.2	42
647	Novel anti-4-1BBÃ—PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade. , 2021, 9, e002428.		26
648	Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes. Cancer Immunology, Immunotherapy, 2022, 71, 445-459.	2.0	13
649	Predictive factors of neoadjuvant immune checkpoint blockade in melanoma. Human Vaccines and Immunotherapeutics, 2022, 18, 1-9.	1.4	3
651	Neutrophils in the era of immune checkpoint blockade. , 2021, 9, e002242.		52
652	Synergies between therapeutic ultrasound, gene therapy and immunotherapy in cancer treatment. Advanced Drug Delivery Reviews, 2021, 178, 113906.	6.6	20
653	Immune cell profiling in atherosclerosis: role in research and precision medicine. Nature Reviews Cardiology, 2022, 19, 43-58.	6.1	58
654	CD8+ T cell differentiation and dysfunction in cancer. Nature Reviews Immunology, 2022, 22, 209-223.	10.6	345
655	Debulking surgery for malignant tumors: the current status, evidence and future perspectives. Japanese Journal of Clinical Oncology, 2021, 51, 1349-1362.	0.6	6
656	A human CD137Ã—PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade. Nature Communications, 2021, 12, 4445.	5.8	54
657	Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors. Frontiers in Pharmacology, 2021, 12, 678409.	1.6	15
658	Evolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer. , 0, , .		4
659	Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 689727.	1.8	20
660	Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma. Cancers, 2021, 13, 3676.	1.7	13
661	Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors. Scientific Reports, 2021, 11, 15312.	1.6	15

#	Article	IF	Citations
662	Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy. International Journal of Molecular Sciences, 2021, 22, 8017.	1.8	15
663	First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 417-431.	2.0	6
664	Instruction of Immunometabolism by Adipose Tissue: Implications for Cancer Progression. Cancers, 2021, 13, 3327.	1.7	4
665	Characterizing the Metabolic and Immune Landscape of Non-small Cell Lung Cancer Reveals Prognostic Biomarkers Through Omics Data Integration. Frontiers in Cell and Developmental Biology, 2021, 9, 702112.	1.8	7
666	Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer. , 2021, 9, e002474.		34
667	Proteomic profiles of melanoma cell-derived exosomes in plasma: discovery of potential biomarkers of melanoma progression. Melanoma Research, 2021, 31, 472-475.	0.6	4
668	Standard Peripheral Blood Mononuclear Cell Cryopreservation Selectively Decreases Detection of Nine Clinically Relevant T Cell Markers. ImmunoHorizons, 2021, 5, 711-720.	0.8	10
669	An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity. Cancer Immunology Research, 2021, 9, 1141-1157.	1.6	33
670	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Science Translational Medicine, 2021, 13, .	5.8	54
671	Vascular Normalization: A New Window Opened for Cancer Therapies. Frontiers in Oncology, 2021, 11, 719836.	1.3	39
672	Use of Antibiotics during Immune Checkpoint Inhibitor Treatment Is Associated with Lower Survival in Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 606-614.	4.2	30
673	Antifibrotic Therapy Augments the Antitumor Effects of Vesicular Stomatitis Virus Via Reprogramming Tumor Microenvironment. Human Gene Therapy, 2022, 33, 237-249.	1.4	2
674	Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. European Journal of Cancer, 2021, 153, 8-15.	1.3	1
675	Impacto de los nuevos tratamientos y la adyuvancia en las estrategias de estadificaciÃ³n y seguimiento del paciente con melanoma. Piel, 2021, 36, 435-437.	0.0	0
676	Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2021, 22, 9414.	1.8	46
677	Pattern of disease and response to pembrolizumab in recurrent cervical cancer. Gynecologic Oncology Reports, 2021, 37, 100831.	0.3	4
678	Immune checkpoint inhibitors use and effects on prognosis of COVID-19 infection: a systematic review and meta-analysis. Immunotherapy, 2021, 13, 1271-1282.	1.0	13
679	Translational Insights and New Therapeutic Perspectives in Head and Neck Tumors. Biomedicines, 2021, 9, 1045.	1.4	4

#	Article	IF	Citations
680	A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups. Frontiers in Oncology, 2021, 11, 696147.	1.3	10
681	The Ratio of Exhausted to Resident Infiltrating Lymphocytes Is Prognostic for Colorectal Cancer Patient Outcome. Cancer Immunology Research, 2021, 9, 1125-1140.	1.6	18
682	Re-Evaluating the Effects of Obesity on Cancer Immunotherapy Outcomes in Renal Cancer: What Do We Really Know?. Frontiers in Immunology, 2021, 12, 668494.	2.2	12
683	BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. Journal of Clinical Investigation, 2021, 131, .	3.9	45
684	Clinical Perspectives of Single-Cell RNA Sequencing. Biomolecules, 2021, 11, 1161.	1.8	11
685	Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms. Frontiers in Cardiovascular Medicine, 2021, 8, 721333.	1.1	14
686	Pembrolizumab and Ipilimumab as Second-Line Therapy for Advanced Melanoma. Journal of Clinical Oncology, 2021, 39, 2637-2639.	0.8	4
687	A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma. Oral Oncology, 2021, 119, 105366.	0.8	31
689	The Effect of Pembrolizumab Plus Platinum-based Chemotherapy on the Progression-free Survival of Non-small-cell Lung Cancer with a High PD-L1 Expression and Large Baseline Tumor Size. Japanese Journal of Lung Cancer, 2021, 61, 289-296.	0.0	0
690	Inhibition of Cyclin Dependent Kinase 4/6 Overcomes Primary Resistance to Programmed Cell Death 1 Blockade in Malignant Mesothelioma. Annals of Thoracic Surgery, 2022, 114, 1842-1852.	0.7	14
691	Tumor-draining lymph nodes: At the crossroads of metastasis and immunity. Science Immunology, 2021, 6, eabg3551.	5.6	85
692	Unraveling the Multifaceted Nature of CD8 T Cell Exhaustion Provides the Molecular Basis for Therapeutic T Cell Reconstitution in Chronic Hepatitis B and C. Cells, 2021, 10, 2563.	1.8	12
693	Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial Cancer. Cancers, 2021, 13, 4660.	1.7	2
694	N6-Methyladenosine RNA Modification: An Emerging Immunotherapeutic Approach to Turning Up Cold Tumors. Frontiers in Cell and Developmental Biology, 2021, 9, 736298.	1.8	7
695	PD-1 inhibition in advanced myeloproliferative neoplasms. Blood Advances, 2021, 5, 5086-5097.	2.5	16
696	Immunological exhaustion: How to make a disparate concept operational?. PLoS Pathogens, 2021, 17, e1009892.	2.1	11
697	Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. Frontiers in Oncology, 2021, 11, 716844.	1.3	12
698	Active surveillance characterizes human intratumoral T cell exhaustion. Journal of Clinical Investigation, 2021, 131, .	3.9	22

#	Article	IF	Citations
699	Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates. , 2021, 9, e003122.		9
700	Developing a Conceptual Model for the Post-COVID-19 Pandemic Changing Tourism Risk Perception. International Journal of Environmental Research and Public Health, 2021, 18, 9824.	1.2	17
701	Editorial: CD4+ T Cells in Cancer Immunotherapies. Frontiers in Immunology, 2021, 12, 737615.	2.2	3
702	Resident memory CD8+ TÂcells in regional lymph nodes mediate immunity to metastatic melanoma. Immunity, 2021, 54, 2117-2132.e7.	6.6	50
703	Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ TÂcells in tumor-draining lymph nodes. Immunity, 2021, 54, 2338-2353.e6.	6.6	111
704	Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 6761-6771.	3.2	33
705	Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8 ⁺ T cell clone size and cytotoxicity. Science Immunology, 2021, 6, eabj8825.	5.6	41
706	Mathematical modeling approach of cancer immunoediting reveals new insights in targeted-therapy and timing plan of cancer treatment. Chaos, Solitons and Fractals, 2021, 152, 111349.	2.5	3
707	Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape. Journal of Molecular and Cellular Cardiology, 2021, 160, 121-127.	0.9	6
708	Personalized cancer immunotherapy. , 2022, , 399-426.		0
709	Immune checkpoint blockade therapy in high-grade glioma. , 2022, , 91-108.		0
710	Cross-Talk Between Interferon-Gamma and IL-2 Signaling Regulates Antigen-Specific CD8 ⁺ T-Cell Number. SSRN Electronic Journal, 0, , .	0.4	1
711	Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients. Cancer Immunology, Immunotherapy, 2021, 70, 2095-2102.	2.0	17
712	Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer. Theranostics, 2021, 11, 4155-4170.	4.6	84
713	PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642199368.	1.5	9
714	Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nature Medicine, 2021, 27, 152-164.	15.2	451
715	Hematopoietic versus Solid Cancers and T Cell Dysfunction: Looking for Similarities and Distinctions. Cancers, 2021, 13, 284.	1.7	15
716	New cytometry tools for immune monitoring during cancer immunotherapy. Cytometry Part B - Clinical Cytometry, 2021, 100, 10-18.	0.7	11

#	Article	IF	Citations
717	Hyperprogression: A novel response pattern under immunotherapy. Clinical and Translational Medicine, 2020, 10, e167.	1.7	22
718	Metastasectomy for melanoma is associated with improved overall survival in responders to targeted molecular or immunotherapy. Journal of Surgical Oncology, 2020, 122, 555-561.	0.8	8
719	Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors. Methods in Molecular Biology, 2020, 2055, 23-60.	0.4	12
720	Surgical Management of Distant Melanoma Metastases. , 2020, , 1359-1402.		1
721	Cytotoxic CD8+ Lymphocytes in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1224, 53-62.	0.8	56
722	Mechanisms of Resistance to Checkpoint Blockade Therapy. Advances in Experimental Medicine and Biology, 2020, 1248, 83-117.	0.8	22
723	Double immune checkpoint blockade in advanced NSCLC. Critical Reviews in Oncology/Hematology, 2020, 152, 102980.	2.0	12
724	Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response. EBioMedicine, 2021, 64, 103160.	2.7	13
725	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. European Journal of Cancer, 2020, 134, 19-28.	1.3	45
726	Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms. Immunity, 2020, 52, 825-841.e8.	6.6	497
727	The current landscape of single-cell transcriptomics for cancer immunotherapy. Journal of Experimental Medicine, 2021, 218, .	4.2	35
728	Computational modelling of modern cancer immunotherapy. Physics in Medicine and Biology, 2020, 65, 24TR01.	1.6	14
737	Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. JCI Insight, 2018, 3, .	2.3	123
738	Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy. JCI Insight, 2020, 5, .	2.3	58
739	Clinical implications of monitoring nivolumab immunokinetics in nonâ€“small cell lung cancer patients. JCI Insight, 2018, 3, .	2.3	156
740	Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. JCI Insight, 2017, 2, .	2.3	62
741	CX3CR1 identifies PD-1 therapyâ€“responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight, 2018, 3, .	2.3	106
742	U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. Journal of Clinical Investigation, 2019, 130, 374-388.	3.9	43

#	Article	IF	Citations
743	Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. Journal of Clinical Investigation, 2018, 128, 4654-4668.	3.9	591
744	Cancer immunosurveillance by CD8 T cells. F1000Research, 2020, 9, 80.	0.8	11
745	Biomarkers for immune therapy in melanoma. Seminars in Cutaneous Medicine and Surgery, 2018, 37, 120-126.	1.6	2
746	Density of CD3+ and CD8+ cells in gingivo-buccal oral squamous cell carcinoma is associated with lymph node metastases and survival. PLoS ONE, 2020, 15, e0242058.	1.1	17
747	Blockade of programmed cell death protein-1 pathway for the treatment of melanoma. Journal of Antioxidant Activity, 2017, 1, 1-11.	1.0	12
748	SMAR1 promotes immune escape of Tri-negative Breast Cancer through a mechanism involving T-bet/PD-1 Axis. Cellular and Molecular Biology, 2018, 64, 70-75.	0.3	2
749	Systemic CD4 immunity: A powerful clinical biomarker for PDâ€Ł1/PDâ€•1 immunotherapy. EMBO Molecular Medicine, 2020, 12, e12706.	3.3	19
750	Immune Checkpoint Inhibitors in the Treatment of Melanoma: From Basic Science to Clinical Application. , 0, , 121-142.		31
751	A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival. Oncotarget, 2018, 9, 23620-23627.	0.8	19
752	PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy. Oncotarget, 2018, 9, 27460-27470.	0.8	53
753	PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients. Oncotarget, 2018, 9, 32024-32035.	0.8	25
754	Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy. Oncotarget, 2019, 10, 4612-4614.	0.8	11
755	Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors. , 2019, 2, 744-761.		3
756	The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biology and Medicine, 2019, 16, 655-670.	1.4	95
757	Camrelizumabâ€”targeting a novel PD-1 epitope to treat hepatocellular carcinoma. Annals of Translational Medicine, 2020, 8, 1614-1614.	0.7	2
758	Clinical implications of neutrophil-to-lymphocyte ratio and MDSC kinetics in gastric cancer patients treated with ramucirumab plus paclitaxel. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 621-630.	0.7	7
759	Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy. Current Medicinal Chemistry, 2020, 27, 2792-2813.	1.2	12
760	Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer. Anticancer Research, 2019, 39, 815-825.	0.5	73

#	Article	IF	Citations
761	Biomarkers Predicting for Response and Relapse with Melanoma Systemic Therapy. Acta Dermato-Venereologica, 2020, 100, adv00142.	0.6	3
762	Management of cutaneous melanoma: comparison of the leading international guidelines updated to the 8th American Joint Committee on Cancer staging system and workup proposal by the Italian Society of Dermatology. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 126-145.	0.8	5
763	CARâ€'T 19 combined with reducedâ€'dose PDâ€'1 blockade therapy for treatment of refractory follicular lymphoma: A case report. Oncology Letters, 2019, 18, 4415-4420.	0.8	24
764	Immunotherapy-induced acute pulmonary thromboembolism: A case report. South Asian Journal of Cancer, 2019, 08, 172-182.	0.2	6
765	Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy. Immune Network, 2020, 20, e8.	1.6	19
766	Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy. ELife, 2020, 9, .	2.8	40
767	Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model. Cancer Gene Therapy, 2022, 29, 456-465.	2.2	35
768	Programmed death (PD)â€1/PDâ€ligand 1 blockade mediates antiangiogenic effects by tumorâ€derived CXCL10/11 as a potential predictive biomarker. Cancer Science, 2021, 112, 4853-4866.	1.7	6
770	Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L). BMC Cancer, 2021, 21, 1121.	1.1	3
771	Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab. , 2021, 9, e002663.		9
772	Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases. Nature Communications, 2021, 12, 5955.	5.8	25
774	Benefits and Pitfalls of Tumor Vessel Normalization. , 2018, , 1-21.		0
775	Are lung adenocarcinoma mutations shaping the immune microenvironment?. Translational Cancer Research, 2018, 7, S740-S742.	0.4	2
776	Radiation and Immunotherapy for Sarcoma. , 2019, , 47-65.		0
777	Personalized Cancer Immunotherapy: Todayâ€™s Challenge and Tomorrowâ€™s Promise. Journal of Immunotherapy and Precision Oncology, 2018, 1, 56-67.	0.6	4
778	Biomarkers for Melanoma. , 2019, , 1-32.		0
779	In Situ Transfection of Interleukin 12 Plasmid Enhances Anti-PD-1 Immune Response in Patients with Immunologically Quiescent Melanoma. SSRN Electronic Journal, 0, , .	0.4	0
780	Surgical Management of Distant Melanoma Metastases. , 2019, , 1-44.		0

#	Article	IF	Citations
781	Benefits and Pitfalls of Tumor Vessel Normalization. , 2019, , 51-71.		1
786	The Laboratory Evaluation of Melanoma. , 2021, , 29-60.		0
789	IMMUNOTERAPÄ° VE RADYOTERAPÄ° KOMBÄ°NASYONU. UludaÄŸ Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 0, , .	0.2	1
790	Biomarkers for Immune Checkpoint Inhibitors. , 2021, , 449-463.		0
792	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell, 2021, 39, 1497-1518.e11.	7.7	126
793	New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy. Patterns, 2021, 2, 100372.	3.1	22
794	Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. Cancers, 2021, 13, 5415.	1.7	13
795	Peptide hydrogels loaded with irradiated tumor cell secretions enhance cancer immunotherapy. Nano Today, 2021, 41, 101323.	6.2	16
796	T lymphocytes related biomarkers for predicting immunotherapy efficacy in nonâ€‘small cell lung cancer (Review). Oncology Letters, 2020, 21, 89.	0.8	8
799	Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs. Immune Network, 2020, 20, e48.	1.6	10
801	Integrative Modeling of Tumor Burden and Metastatic Pattern for Guiding Anti-PD-L1 Treatment of Nonâ€“Small Cell Lung Cancer: Results From Two Randomized Studies. SSRN Electronic Journal, 0, , .	0.4	0
806	Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	15
807	Radiotherapy and immunotherapy: open questions and future strategies. Trends in Cancer, 2022, 8, 9-20.	3.8	49
808	Circulating predictive markers of immune checkpoint inhibitors in non-small cell lung cancer. Uspehi Molekularnoj Onkologii, 2021, 8, 34-43.	0.1	0
809	Role of debulking surgery in combination with immune therapy: A successfully treated case of locally advanced mucosal melanoma. Molecular and Clinical Oncology, 2021, 16, 2.	0.4	1
813	Considerations for cancer immunotherapy biomarker research during COVID-19. Endocrine-Related Cancer, 2020, 27, C1-C8.	1.6	0
814	Exposure to Tobacco Smoking Induces a subset of Activated Tumor-resident Tregs in Non-Small Cell Lung Cancer. Translational Oncology, 2022, 15, 101261.	1.7	3
815	Tumorâ€derived exosomal PDâ€L1 in progression of cancer and immunotherapy. Journal of Cellular Physiology, 2022, 237, 1648-1660.	2.0	10

#	Article	IF	Citations
816	Neoantigen-driven B cell and CD4ÂT follicular helper cell collaboration promotes anti-tumor CD8 TÂcell responses. Cell, 2021, 184, 6101-6118.e13.	13.5	192
817	A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients. Journal of Experimental Medicine, 2022, 219, .	4.2	37
818	The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer â€“ a study protocol. BMC Cancer, 2021, 21, 1238.	1.1	4
819	Baseline tumour size is an independent prognostic factor for overall survival in PD-L1â€‰â‰¥â€‰50% non-small cell lung cancer patients treated with first-line pembrolizumab. Cancer Immunology, Immunotherapy, 2022, 71, 1747-1756.	2.0	5
820	Predictable Roles of Peripheral IgM Memory B Cells for the Responses to Anti-PD-1 Monotherapy Against Advanced Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 759217.	2.2	18
821	Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patientsâ€™ Survival. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 964-971.	1.8	16
822	CXCL10 chemokine regulates heterogeneity of the CD8+ TÂcell response and viral set point during chronic infection. Immunity, 2022, 55, 82-97.e8.	6.6	33
823	Current and Future Clinical Applications of ctDNA in Immuno-Oncology. Cancer Research, 2022, 82, 349-358.	0.4	57
824	Dynamic CD4+ T cell heterogeneity defines subset-specific suppression and PD-L1-blockade-driven functional restoration in chronic infection. Nature Immunology, 2021, 22, 1524-1537.	7.0	26
825	IFNÎ³ Signaling in Natural and Therapy-Induced Antitumor Responses. Clinical Cancer Research, 2022, 28, 1243-1249.	3.2	15
826	BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment. Cancer Research, 2022, 82, 264-277.	0.4	8
827	Differential Role of PD-1 Expressed by Various Immune and Tumor Cells in the Tumor Immune Microenvironment: Expression, Function, Therapeutic Efficacy, and Resistance to Cancer Immunotherapy. Frontiers in Cell and Developmental Biology, 2021, 9, 767466.	1.8	13
828	Immunotherapies for hepatocellular carcinoma. Nature Reviews Clinical Oncology, 2022, 19, 151-172.	12.5	643
829	Preoperative Use of a Radiation Boost to Enhance Effectiveness of Immune Checkpoint Blockade Therapy in Operable Breast Cancer. Annals of Surgical Oncology, 2021, , 1.	0.7	2
830	Oligoprogression in Non-Small Cell Lung Cancer. Cancers, 2021, 13, 5823.	1.7	15
831	Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy. Annals of Translational Medicine, 2021, 9, 1639-1639.	0.7	4
832	Thymic Function and T-Cell Receptor Repertoire Diversity: Implications for Patient Response to Checkpoint Blockade Immunotherapy. Frontiers in Immunology, 2021, 12, 752042.	2.2	11
833	Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study. Lancet Oncology, The, 2021, 22, 1777-1786.	5.1	75

#	Article	IF	Citations
834	Crossed Pathways for Radiation-Induced and Immunotherapy-Related Lung Injury. Frontiers in Immunology, 2021, 12, 774807.	2.2	22
835	Novel technologies in cfDNA analysis and potential utility in clinic. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 708-718.	0.7	5
836	Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise. Diagnostics, 2022, 12, 124.	1.3	12
837	Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naÃ¯ve advanced non-small-cell lung cancer. European Journal of Cancer, 2022, 161, 44-54.	1.3	7
839	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nature Medicine, 2022, 28, 125-135.	15.2	53
840	A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors. Science Immunology, 2022, 7, eabi6899.	5.6	36
841	Considerations for cancer immunotherapy biomarker research during COVID-19. Endocrine-Related Cancer, 2020, 27, C1-C8.	1.6	0
842	Hollow Mesoporous Manganese Oxides: Application in Cancer Diagnosis and Therapy. Small, 2022, 18, e2106511.	5.2	29
843	Systemic Immune Dysregulation Correlates With Clinical Features of Early Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 754138.	2.2	6
844	Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy. Clinical Cancer Research, 2022, 28, 1353-1362.	3.2	10
845	T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nature Medicine, 2022, 28, 353-362.	15.2	132
846	Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners. Biomedicines, 2022, 10, 307.	1.4	9
847	Preoperative Immune Checkpoint Inhibition and Cryoablation in Early-Stage Breast Cancer. SSRN Electronic Journal, 0, , .	0.4	0
848	A simple, rapid and low-cost qPCR assay for evaluating the severity of exosomal PD-L1-mediated T cell exhaustion in blood samples. Chemical Communications, 2022, 58, 831-834.	2.2	2
849	Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade. OncoImmunology, 2022, 11, 2025668.	2.1	6
850	T cell subtype profiling measures exhaustion and predicts anti-PD-1 response. Scientific Reports, 2022, 12, 1342.	1.6	7
851	Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance. Cells, 2022, 11, 410.	1.8	9
852	Antiâ€PDâ€L1/TGFâ€Î²R fusion protein (SHRâ€1701) overcomes disrupted lymphocyte recoveryâ€induced resistance to PDâ€1/PDâ€L1 inhibitors in lung cancer. Cancer Communications, 2022, 42, 17-36.	3.7	30

#	Article	IF	Citations
853	Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab. Journal of Immunotherapy, 2022, 45, 167-179.	1.2	7
854	Programmed death ligand 1 signals in cancer cells. Nature Reviews Cancer, 2022, 22, 174-189.	12.8	133
855	Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instabilityâ€“High Locally Advanced Rectal Cancer. Clinical Cancer Research, 2022, 28, 1136-1146.	3.2	62
856	TCR-sequencing in cancer and autoimmunity: barcodes and beyond. Trends in Immunology, 2022, 43, 180-194.	2.9	20
857	Immune Response on Optimal Timing and Fractionation Dose for Hypofractionated Radiotherapy in Nonâ€“Small-Cell Lung Cancer. Frontiers in Molecular Biosciences, 2022, 9, 786864.	1.6	5
858	Immune checkpoint blockade in HIV. EBioMedicine, 2022, 76, 103840.	2.7	15
860	DAISM-DNNXMBD: Highly accurate cell type proportion estimation with in silico data augmentation and deep neural networks. Patterns, 2022, 3, 100440.	3.1	10
861	Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Therapy. International Journal of Radiation Oncology Biology Physics, 2022, 113, 415-425.	0.4	9
862	A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 778276.	2.2	6
863	Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review. Cancers, 2021, 13, 6366.	1.7	10
864	Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nature Cancer, 2022, 3, 108-121.	5.7	150
865	<i>In Vivo</i> Activated T Cell Targeting with PD-1/PD-L1 Blockade for Sequential Treatment Mediated Cancer Immunotherapy. SSRN Electronic Journal, 0, , .	0.4	0
866	Comprehensive Immune Landscape and Molecular Characteristics of Clinical Responses to Chemotherapy, Antiangiogenic Agents and PD-1 Inhibitors in Advanced Nasopharyngeal Cancer. SSRN Electronic Journal, 0, , .	0.4	0
867	Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. Cell Reports Medicine, 2022, 3, 100500.	3.3	13
868	Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2). Nature Communications, 2022, 13, 857.	5.8	50
869	Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival. Cancers, 2022, 14, 1237.	1.7	7
870	Nivolumab-DTPA-Based PD-1 Imaging Reveals Structural and Pathological Changes in Colorectal Carcinoma. Frontiers in Bioengineering and Biotechnology, 2022, 10, 839756.	2.0	2
871	Knowns and Unknowns about CAR-T Cell Dysfunction. Cancers, 2022, 14, 1078.	1.7	23

#	Article	IF	Citations
872	Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy. Translational Lung Cancer Research, 2022, 11, 135-149.	1.3	5
873	Whatâ€™s next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination. OncoImmunology, 2022, 11, 2038403.	2.1	7
874	The combination of radiotherapy and immunotherapy is effective and well tolerated for unresectable biliary tract cancer. International Journal of Radiation Oncology Biology Physics, 2022, , .	0.4	2
875	Human epigenetic and transcriptional TÂcell differentiation atlas for identifying functional TÂcell-specific enhancers. Immunity, 2022, 55, 557-574.e7.	6.6	47
876	Meningeal lymphatics regulate radiotherapy efficacy through modulating anti-tumor immunity. Cell Research, 2022, 32, 543-554.	5.7	19
878	A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nature Immunology, 2022, 23, 660-670.	7.0	191
879	Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an antiâ€“programmed cell death protein-1 (PD-1) antibody, in human cancer models. Cancer Chemotherapy and Pharmacology, 2022, 89, 515-527.	1.1	7
880	Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs. , 2022, 136, 212761.		10
881	Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment. Journal of Immunology Research, 2022, 2022, 1-9.	0.9	20
882	Hallmarks of Resistance to Immune-Checkpoint Inhibitors. Cancer Immunology Research, 2022, 10, 372-383.	1.6	36
883	Long-term control of melanoma adrenal metastasis treated with radiotherapy. Melanoma Research, 2022, Publish Ahead of Print, .	0.6	2
884	Selective Targeting of Protein Kinase C (PKC)-Î¸ Nuclear Translocation Reduces Mesenchymal Gene Signatures and Reinvigorates Dysfunctional CD8+ T Cells in Immunotherapy-Resistant and Metastatic Cancers. Cancers, 2022, 14, 1596.	1.7	3
885	How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC. Clinical Immunology, 2022, 237, 108962.	1.4	16
887	Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma. Clinical Cancer Research, 2022, 28, 2567-2578.	3.2	20
888	Towards a precision immune checkpoint blockade immunotherapy in patients with colorectal cancer: Strategies and perspectives. Biomedicine and Pharmacotherapy, 2022, 149, 112923.	2.5	7
889	Nanotechnology-based multifunctional vaccines for cancer immunotherapy. Chemical Engineering Journal, 2022, 437, 135505.	6.6	13
890	Multimodal predictors for precision immunotherapy. Immuno-Oncology Technology, 2022, 14, 100071.	0.2	4
891	Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy. , 2021, 9, e003439.		10

#	Article	IF	Citations
892	Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer. , 2021, 9, e002780.		15
893	Single-Cell Transcriptome Analysis Reveals RGS1 as a New Marker and Promoting Factor for T-Cell Exhaustion in Multiple Cancers. Frontiers in Immunology, 2021, 12, 767070.	2.2	29
894	NKG7 Is a T-cellâ€“Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy. Cancer Immunology Research, 2022, 10, 162-181.	1.6	26
895	Mathematical modelling of tumour-immune interactions in presence of checkpoint inhibitor-based therapies for the treatment of cancer. Materials Today: Proceedings, 2021, , .	0.9	0
896	Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment. Pharmaceutics, 2022, 14, 41.	2.0	27
897	The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint blockade. Immunity, 2022, 55, 671-685.e10.	6.6	35
898	Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. Nature Communications, 2022, 13, 1935.	5.8	37
899	Data-driven learning how oncogenic gene expression locally alters heterocellular networks. Nature Communications, 2022, 13, 1986.	5.8	3
901	Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. Cancer Discovery, 2022, 12, 1248-1265.	7.7	36
902	Enhancer RNAs (eRNAs) in Cancer: The Jacks of All Trades. Cancers, 2022, 14, 1978.	1.7	6
943	Optimal systemic therapy for high-risk resectable melanoma. Nature Reviews Clinical Oncology, 2022, 19, 431-439.	12.5	12
944	Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitorâ€“Induced Synthetic Lethality. Cancer Research, 2022, 82, 2156-2170.	0.4	23
947	Decoding the functional role of extracellular vesicles in hepatocellular carcinoma: implications in clinical theranostics. , 2022, , 301-339.		0
948	Melanoma: An immunotherapyÂjourney from bench to bedside. Cancer Treatment and Research, 2022, 183, 49-89.	0.2	0
949	Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial). BMC Cancer, 2022, 22, 462.	1.1	10
950	Interferons limit autoantigen-specific CD8+ T-cell expansion in the non-obese diabetic mouse. Cell Reports, 2022, 39, 110747.	2.9	3
951	Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine. Cancers, 2022, 14, 2241.	1.7	26
952	The Cellular Tumor Immune Microenvironment of Childhood Solid Cancers: Informing More Effective Immunotherapies. Cancers, 2022, 14, 2177.	1.7	2

#	Article	IF	Citations
953	Advanced materials for management of immune-related adverse events induced by immune checkpoint inhibitors. Materials and Design, 2022, 219, 110738.	3.3	0
954	Spatial determinants of CD8+ T cell differentiation in cancer. Trends in Cancer, 2022, 8, 642-654.	3.8	8
955	An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors. Clinical Cancer Research, 2022, 28, 3053-3065.	3.2	26
956	Redistribution of <scp>CD8</scp>+ T cell subsets in metastatic renal cell carcinoma patients treated with <scp>antiâ€PD</scp>â€1 therapy. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2022, 101, 597-605.	1.1	2
957	Tumour immunotherapy: lessons from predatorâ€“prey theory. Nature Reviews Immunology, 2022, 22, 765-775.	10.6	41
958	Integration of Tumor Microenvironment in Patient-Derived Organoid Models Help Define Precision Medicine of Renal Cell Carcinoma. Frontiers in Immunology, 2022, 13, 902060.	2.2	3
959	High-throughput single-Ñell sequencing in cancer research. Signal Transduction and Targeted Therapy, 2022, 7, 145.	7.1	39
960	In vivo activated T cell targeting with PD-1/PD-L1 blockade for sequential treatment mediated cancer immunotherapy. Nano Today, 2022, 44, 101492.	6.2	7
961	The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine. Biomedicine and Pharmacotherapy, 2022, 150, 113064.	2.5	14
962	Advances of research of Fc-fusion protein that activate NK cells for tumor immunotherapy. International Immunopharmacology, 2022, 109, 108783.	1.7	8
963	OX40 enhances T cell immune response to PD-1 blockade therapy in non-small cell lung cancer. International Immunopharmacology, 2022, 108, 108813.	1.7	7
964	Identification of AKIRIN2 as a potential biomarker and correlation with immunotherapy in gastric adenocarcinoma by integrated bioinformatics analysis. Scientific Reports, 2022, 12, 8400.	1.6	1
965	Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells. Cancer Immunology Research, 2022, 10, 885-899.	1.6	7
966	Crosstalk between ILâ€15RÎ±⁺tumorâ€associated macrophages and breast cancer cells reduces CD8⁺T cell recruitment. Cancer Communications, 2022, 42, 536-557.	3.7	15
967	Bleeding complications and possible resistance patterns of anti-angiogenesis treatments in recurrent/metastatic head-and-neck squamous cell carcinoma â€“ Reflections from a phase II study of pazopanib in recurrent/metastatic head-and-neck squamous cell carcinoma. Journal of Cancer Research and Practice, 2022, 9, 52.	0.2	1
968	Loco-Regional Therapies in Oligometastatic Adrenocortical Carcinoma. Cancers, 2022, 14, 2730.	1.7	5
969	The paradox of immune checkpoint inhibition re-activating tuberculosis. European Respiratory Journal, 2022, 60, 2102512.	3.1	8
970	â€˜Stem-likeâ€™ precursors are the fount to sustain persistent CD8+ T cell responses. Nature Immunology, 2022, 23, 836-847.	7.0	50

#	Article	IF	Citations
971	T-Cell Repertoire in Tumor Radiation: The Emerging Frontier as a Radiotherapy Biomarker. Cancers, 2022, 14, 2674.	1.7	5
972	Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE). Frontiers in Immunology, 2022, 13, .	2.2	21
973	Case Report: Immune Checkpoint Blockade Plus Interferon-Î“ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis. Frontiers in Immunology, 0, 13, .	2.2	11
974	Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). , 2022, 10, e004226.		9
975	Dynamic Changes of Peripheral NK Cells Predict Outcome in Patients with PD-L1 Positive Non-small-cell Lung Cancer Undergoing Immune Checkpoint Inhibitors as Second-line Therapy. Cancer Investigation, 2022, 40, 710-721.	0.6	1
976	Single B Cell Gene Co-Expression Networks Implicated in Prognosis, Proliferation, and Therapeutic Responses in Non-Small Cell Lung Cancer Bulk Tumors. Cancers, 2022, 14, 3123.	1.7	5
977	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nature Reviews Drug Discovery, 2022, 21, 529-540.	21.5	134
978	Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer. Biomedicines, 2022, 10, 1419.	1.4	3
979	Predicting the efficacy of <scp>firstâ€line</scp> immunotherapy by combining cancer cachexia and tumor burden in advanced <scp>nonâ€small cell</scp> lung cancer. Thoracic Cancer, 2022, 13, 2064-2074.	0.8	7
980	Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges. Seminars in Cancer Biology, 2022, 86, 477-490.	4.3	10
981	CLEC1B is a Promising Prognostic Biomarker and Correlated with Immune Infiltration in Hepatocellular Carcinoma. International Journal of General Medicine, 0, Volume 15, 5661-5672.	0.8	3
982	Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system. Journal of Clinical Pharmacy and Therapeutics, 0, , .	0.7	2
983	Humanized Ovarian Cancer Patient-Derived Xenografts for Improved Preclinical Evaluation of Immunotherapies. Cancers, 2022, 14, 3092.	1.7	5
984	Tumour burden and antigen-specific T cell magnitude represent major parameters for clinical response to cancer vaccine and TCR-engineered T cell therapy. European Journal of Cancer, 2022, 171, 96-105.	1.3	3
985	Realâ€world utilization of <scp>PD</scp>â€1/<scp>PDâ€L1</scp> inhibitors with palliative radiotherapy in patients with metastatic nonâ€small cell lung cancer. Thoracic Cancer, 2022, 13, 2291-2300.	0.8	7
986	Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems. Journal of Personalized Medicine, 2022, 12, 1073.	1.1	36
987	Neoadjuvant Immunotherapy for Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 0, Volume 9, 571-581.	1.8	10
988	Immune organoids: from tumor modeling to precision oncology. Trends in Cancer, 2022, 8, 870-880.	3.8	16

#	Article	IF	Citations
989	Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC. Cancers, 2022, 14, 3332.	1.7	11
990	Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Nonâ€“Small Cell Lung Cancer. Frontiers in Immunology, 0, 13, .	2.2	8
991	Recent progress on the activation of the cGASâ€“STING pathway and its regulation by biomolecular condensation. Journal of Molecular Cell Biology, 2022, 14, .	1.5	5
993	Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma. Radiation Oncology, 2022, 17, .	1.2	8
994	Clinical impact of tumour burden on the efficacy of <scp>PD</scp> â€1/ <scp>PDâ€L1</scp> inhibitors plus chemotherapy in nonâ€smallâ€cell lung cancer. Cancer Medicine, 0, , .	1.3	1
995	Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade. Frontiers in Immunology, 0, 13, .	2.2	2
996	Facts and Hopes for Immunotherapy in Renal Cell Carcinoma. Clinical Cancer Research, 2022, 28, 5013-5020.	3.2	8
997	Blood T-cell profiling in metastatic melanoma patients as a marker for response to immune checkpoint inhibitors combined with radiotherapy. Radiotherapy and Oncology, 2022, 173, 299-305.	0.3	7
998	Stepwise Size Shrinkage Cascadeâ€Activated Supramolecular Prodrug Boosts Antitumor Immunity by Eliciting Pyroptosis. Advanced Science, 2022, 9, .	5.6	35
999	Techniques for Profiling the Cellular Immune Response and Their Implications for Interventional Oncology. Cancers, 2022, 14, 3628.	1.7	4
1000	Immunotherapy-induced Hepatotoxicity: A Review. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	0.7	3
1001	A â€˜Hybridâ€™ Radiotherapy Regimen Designed for Immunomodulation: Combining High-Dose Radiotherapy with Low-Dose Radiotherapy. Cancers, 2022, 14, 3505.	1.7	3
1002	CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment. Frontiers in Immunology, 0, 13, .	2.2	6
1003	Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines. OncoImmunology, 2022, 11, .	2.1	9
1004	Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial. Digestive and Liver Disease, 2022, 54, 1335-1341.	0.4	12
1005	PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine. Nature Immunology, 2022, 23, 1183-1192.	7.0	36
1006	Interaction of Radiotherapy and Hyperthermia with the Immune System: a Brief Current Overview. Current Stem Cell Reports, 2022, 8, 129-138.	0.7	1
1007	Single-cell analysis of peripheral CD8+ T cell responses in patients receiving checkpoint blockade immunotherapy for cancer. Cancer Immunology, Immunotherapy, 2023, 72, 397-408.	2.0	3

#	Article	IF	Citations
1008	Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood. , 2022, 10, e004803.		15
1009	Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2023, 72, 371-384.	2.0	7
1010	Synergistic effects of radiotherapy and targeted immunotherapy in improving tumor treatment efficacy: a review. Clinical and Translational Oncology, 2022, 24, 2255-2271.	1.2	6
1011	Stem-like T cells and niches: Implications in human health and disease. Frontiers in Immunology, 0, 13, .	2.2	2
1012	Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Frontiers in Oncology, 0, 12, .	1.3	32
1013	New advances in pharmaceutical strategies for sensitizing <scp>antiâ€PD</scp>â€1 immunotherapy and clinical research. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2023, 15, .	3.3	3
1014	Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium. Cancer Research Communications, 2022, 2, 1293-1303.	0.7	2
1015	Escherichia coliâ€“Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer. Cancer Discovery, 2022, 12, 2280-2307.	7.7	23
1016	Differential distribution and prognostic value of CD4+ T cell subsets before and after radioactive iodine therapy in differentiated thyroid cancer with varied curative outcomes. Frontiers in Immunology, 0, 13, .	2.2	2
1017	A Comparison of 2 Disease Burden Assessment Methods (3D Volume Versus the Number of Lesions) for Prognostication of Survival in Metastatic Melanoma: Implications for the Characterization of Oligometastatic Disease. International Journal of Radiation Oncology Biology Physics, 2022, 114, 883-891.	0.4	9
1018	A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer. Cancer Immunology, Immunotherapy, 2023, 72, 759-767.	2.0	3
1019	Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma. EBioMedicine, 2022, 83, 104235.	2.7	11
1020	The evolving role of liquid biopsy in lung cancer. Lung Cancer, 2022, 172, 53-64.	0.9	19
1022	Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study. Frontiers in Oncology, 0, 12, .	1.3	13
1023	Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade. Frontiers in Oncology, 0, 12, .	1.3	2
1024	Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial. Lancet Oncology, The, 2022, 23, 1287-1296.	5.1	18
1025	A cell-laden hydrogel as prophylactic vaccine and anti-PD-L1 amplifier against autologous tumors. Journal of Controlled Release, 2022, 351, 231-244.	4.8	5
1026	Efficacy optimization of low frequency microbubble-mediated sonoporation as a drug delivery platform to cancer cells. International Journal of Pharmaceutics: X, 2022, 4, 100132.	1.2	6

#	Article	IF	Citations
1027	Neoadjuvant Therapy for Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 0, Volume 9, 929-946.	1.8	15
1028	Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors. Scientific Reports, 2022, 12, .	1.6	7
1029	Histochemistry in Advanced Cytometry: From Fluorochromes to Mass Probes. Methods in Molecular Biology, 2023, , 1-25.	0.4	0
1030	Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer. Frontiers in Oncology, 0, 12, .	1.3	3
1031	An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery. Journal of Experimental Medicine, 2022, 219, .	4.2	9
1032	TCR repertoire and transcriptional signatures of circulating tumourâ€associated T cells facilitate effective nonâ€invasive cancer detection. Clinical and Translational Medicine, 2022, 12, .	1.7	2
1033	Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). , 2022, 10, e005413.		6
1034	The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Frontiers in Immunology, 0, 13, .	2.2	83
1035	Loss of CD47 alters CD8+ T cell activation in vitro and immunodynamics in mice. OncoImmunology, 2022, 11, .	2.1	10
1037	The new progress in cancer immunotherapy. Clinical and Experimental Medicine, 2023, 23, 553-567.	1.9	6
1038	Functional and embedding feature analysis for pan-cancer classification. Frontiers in Oncology, 0, 12, .	1.3	2
1039	Manganese Coordination Micelles That Activate Stimulator of Interferon Genes and Capture In Situ Tumor Antigens for Cancer Metalloimmunotherapy. ACS Nano, 2022, 16, 16909-16923.	7.3	37
1040	Emerging roles for IL-25 and IL-33 in colorectal cancer tumorigenesis. Frontiers in Immunology, 0, 13, .	2.2	12
1041	Identification of LAT/ZAP70 characterized immune subtypes of prostate cancer. World Journal of Urology, 2022, 40, 2817-2824.	1.2	1
1043	The Characteristics and Mortality of Chinese Herbal Medicine Users among Newly Diagnosed Inoperable Huge Hepatocellular Carcinoma (â‰¥10 cm) Patients: A Retrospective Cohort Study with Exploration of Core Herbs. International Journal of Environmental Research and Public Health, 2022, 19, 12480.	1.2	3
1044	A Hybrid Discreteâ€“Continuum Modelling Approach to Explore the Impact of T-Cell Infiltration on Anti-tumour Immune Response. Bulletin of Mathematical Biology, 2022, 84, .	0.9	3
1045	Translational Research in Cancer Immunotherapies. Japanese Journal of Lung Cancer, 2022, 62, 363-370.	0.0	0
1046	Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers. Cancers, 2022, 14, 4830.	1.7	1

#	Article	IF	Citations
1047	Low-dose anti-VEGFR2 therapy promotes anti-tumor immunity in lung adenocarcinoma by down-regulating the expression of layilin on tumor-infiltrating CD8+T cells. Cellular Oncology (Dordrecht), 2022, 45, 1297-1309.	2.1	4
1048	Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors. Frontiers in Immunology, 0, 13, .	2.2	2
1049	Machine learning on syngeneic mouse tumor profiles to model clinical immunotherapy response. Science Advances, 2022, 8, .	4.7	6
1050	Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy. International Journal of Molecular Sciences, 2022, 23, 13241.	1.8	9
1051	Relation of overall tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab treatment for lung cancer. Investigational New Drugs, 2022, 40, 1315-1321.	1.2	2
1052	Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancer. Investigational New Drugs, 2022, 40, 1298-1305.	1.2	5
1053	Clinical implications of T cell exhaustion for cancer immunotherapy. Nature Reviews Clinical Oncology, 2022, 19, 775-790.	12.5	182
1054	Pinus roxburghii and Nauplius graveolens Extracts Elevate Apoptotic Gene Markers in C26 Colon Carcinoma Cells Induced in a BALB/c Mouse Model. Separations, 2022, 9, 277.	1.1	2
1055	Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to generate tumor-specific immunity. Science Immunology, 2022, 7, .	5.6	12
1056	A Novel Class of On-Treatment Cancer Immunotherapy Biomarker: Trough Levels of Antibody Therapeutics in Peripheral Blood. Immunological Investigations, 2022, 51, 2159-2175.	1.0	3
1057	Changes in the Immune Cell Repertoire for the Treatment of Malignant Melanoma. International Journal of Molecular Sciences, 2022, 23, 12991.	1.8	3
1058	Silver nano-reporter enables simple and ultrasensitive profiling of microRNAs on a nanoflower-like microelectrode array on glass. Journal of Nanobiotechnology, 2022, 20, .	4.2	4
1059	Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan. Gastric Cancer, 2023, 26, 132-144.	2.7	2
1060	Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors. , 2022, 10, e005548.		9
1061	Near complete remission of a locally advanced giant melanoma of the vulva following hypoâ€fractionated radiotherapy and immune checkpoint inhibitors: A case report. Oncology Letters, 2022, 24, .	0.8	1
1062	Preclinical Study of Plasmodium Immunotherapy Combined with Radiotherapy for Solid Tumors. Cells, 2022, 11, 3600.	1.8	1
1063	Immune responses to tumor-unrelated antigens might predict adverse effects in patients treated with anti-PD-1 immunotherapy. , 0, , .		0
1064	Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis. Medicine (United States), 2022, 101, e31479.	0.4	2

#	Article	IF	Citations
1065	Distinct Dynamics of Migratory Response to PD-1 and CTLA-4 Blockade Reveals New Mechanistic Insights for Potential T-Cell Reinvigoration following Immune Checkpoint Blockade. Cells, 2022, 11, 3534.	1.8	1
1067	Telomerase Reverse Transcriptase in Humans: From Biology to Cancer Immunity. , 2022, , .		0
1068	Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative review. Current Research in Pharmacology and Drug Discovery, 2023, 4, 100146.	1.7	1
1069	Immune profile analysis of peripheral blood and tumors of lung cancer patients treated with immune checkpoint inhibitors. Translational Lung Cancer Research, 2022, 11, 2192-2207.	1.3	1
1071	Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity. International Journal of Molecular Sciences, 2022, 23, 14504.	1.8	5
1072	Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group). BMC Cancer, 2022, 22, .	1.1	2
1073	Attenuated Salmonella potentiate PD-L1 blockade immunotherapy in a preclinical model of colorectal cancer. Frontiers in Immunology, 0, 13, .	2.2	6
1074	IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma. Nature Medicine, 2022, 28, 2592-2600.	15.2	22
1075	Integrated molecular analyses of an interferon-Î³ based subtype with regard to outcome, immune characteristics, and immunotherapy in bladder cancer and experimental verification. Heliyon, 2022, 8, e12102.	1.4	0
1076	Hepatocellular carcinoma complicated with huge posterior pancreas head lymph node metastasis and primary renal carcinoma: A case report. Frontiers in Oncology, 0, 12, .	1.3	0
1077	Discovery and Validation of a SIT1-Related Prognostic Signature Associated with Immune Infiltration in Cutaneous Melanoma. Journal of Personalized Medicine, 2023, 13, 13.	1.1	0
1078	Tumor thickness in mesothelioma predicts differential response to neoadjuvant therapy and survival. Journal of Thoracic and Cardiovascular Surgery, 2023, 166, 362-371.e9.	0.4	2
1079	Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy. Cancer Immunology Research, 2023, 11, 164-170.	1.6	5
1080	The role of surveillance imaging for resected highâ€risk melanoma. Asia-Pacific Journal of Clinical Oncology, 2023, 19, 566-573.	0.7	0
1081	Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 0, 15, 1-18.	0.8	0
1082	Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood. Immunotherapy Advances, 2023, 3, .	1.2	3
1083	PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent nonâ€muscleâ€invasive bladder cancer. BJUI Compass, 2023, 4, 322-330.	0.7	3
1084	Cannabinoid receptor 2 plays a pro-tumorigenic role in non-small cell lung cancer by limiting anti-tumor activity of CD8+ T and NK cells. Frontiers in Immunology, 0, 13, .	2.2	13

#	Article	IF	Citations
1086	A nanoadjuvant that dynamically coordinates innate immune stimuli activation enhances cancer immunotherapy and reduces immune cell exhaustion. Nature Nanotechnology, 2023, 18, 390-402.	15.6	18
1087	Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors. Seminars in Immunopathology, 0, , .	2.8	2
1088	Oligometastasis: More Lessons to Be Learned. Cancer Research and Treatment, 2023, 55, 1-4.	1.3	1
1089	Cutting Edge: Promoting T Cell Factor 1+ T Cell Self-Renewal to Improve Programmed Cell Death Protein 1 Blockade. Journal of Immunology, 2022, 209, 660-664.	0.4	5
1090	Preclinical Platform Using a Triple-negative Breast Cancer Syngeneic Murine Model to Evaluate Immune Checkpoint Inhibitors. Anticancer Research, 2023, 43, 85-95.	0.5	0
1091	A 3D Ex Vivo Tumorâ€Immune Coculture System Mimicking In Vivo Tumor Environmental Stress on CD8+ T Cells Exhaustion. Advanced Biology, 2023, 7, .	1.4	1
1092	Esophageal stenosis as an independent factor of poor prognosis in patients with ESCC treated with definitive chemoradiotherapy. Future Oncology, 2022, 18, 4193-4207.	1.1	1
1093	Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. , 2023, 11, e005924.		24
1094	Liquid biopsy and immunotherapy: is all that glitter gold?. , 2023, , 83-117.		0
1096	Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592311518.	1.4	6
1097	Genetic deletion of HVEM in a leukemia B cell line promotes a preferential increase of PD-1- stem cell-like T cells over PD-1+ T cells curbing tumor progression. Frontiers in Immunology, 0, 14, .	2.2	0
1098	Highlights into historical and current immune interventions for cancer. International Immunopharmacology, 2023, 117, 109882.	1.7	2
1099	Combining radiation therapy with immune checkpoint blockade for the treatment of small cell lung cancer. Seminars in Cancer Biology, 2023, 90, 45-56.	4.3	5
1100	Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis â€“ The challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging. Neoplasia, 2023, 39, 100892.	2.3	1
1101	An attitude-behavioral model to understand peopleâ€™s behavior towards tourism during COVID-19 pandemic. Journal of Business Research, 2023, 161, 113839.	5.8	5
1102	Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Med, 2023, 4, 113-129.e7.	2.2	31
1103	CXCR3 Expression Is Associated with Advanced Tumor Stage and Grade Influencing Survival after Surgery of Localised Renal Cell Carcinoma. Cancers, 2023, 15, 1001.	1.7	1
1104	Combination IFNÎ² and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity. Cancer Immunology Research, 2023, 11, 466-485.	1.6	1

#	Article	IF	Citations
1105	Implications of recent neoadjuvant clinical trials on the future practice of radiotherapy in locally advanced rectal cancer. World Journal of Gastroenterology, 0, 29, 1011-1025.	1.4	5
1107	Revisiting the Role of the CXCL13/CXCR5-Associated Immune Axis in Melanoma: Potential Implications for Anti-PD-1-Related Biomarker Research. Life, 2023, 13, 553.	1.1	2
1108	Advances in the Study of Hyperprogression of Different Tumors Treated with PD-1/PD-L1 Antibody and the Mechanisms of Its Occurrence. Cancers, 2023, 15, 1314.	1.7	2
1110	Peripheral blood lymphocyte changes after stereotactic ablative body radiotherapy to lung or liver metastases in patients with oligometastatic cancers. Radiation Oncology Journal, 2023, 41, 23-31.	0.7	2
1111	Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer. Npj Precision Oncology, 2023, 7, .	2.3	5
1112	Acral Melanoma Is Infiltrated with cDC1s and Functional Exhausted CD8 T Cells Similar to the Cutaneous Melanoma of Sun-Exposed Skin. International Journal of Molecular Sciences, 2023, 24, 4786.	1.8	0
1113	Tâ€cell exhaustion: A potential target biomarker of the tumour microenvironment affecting oesophageal adenocarcinoma. Journal of Gene Medicine, 2023, 25, .	1.4	2
1114	Metabolic reprogramming via an engineered PGC-1Î± improves human chimeric antigen receptor T-cell therapy against solid tumors. , 2023, 11, e006522.		8
1115	Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial. EBioMedicine, 2023, 90, 104515.	2.7	8
1116	Dynamic CD8+ TÂcell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell, 2023, 186, 1127-1143.e18.	13.5	71
1117	Immunotherapy for hepatocellular carcinoma: Recent advances and future targets. , 2023, 244, 108387.		12
1118	Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies. Frontiers in Oncology, 0, 13, .	1.3	5
1119	T cells in the heterogeneous tumour immune microenvironment of hepatocellular carcinoma: Implications for immune checkpoint inhibitor therapy. Liver Cancer International, 2023, 4, 58-72.	0.2	0
1120	CD4+ T cells in cancer. Nature Cancer, 2023, 4, 317-329.	5.7	68
1121	Routine imaging guided by a 31-gene expression profile assay results in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies. Archives of Dermatological Research, 2023, 315, 2295-2302.	1.1	2
1122	Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Current Medical Science, 0, , .	0.7	0
1123	Combining immunotherapy and radiotherapy in hepatocellular carcinoma: the importance of irradiated tumor burden and the possible role of a low dose radiotherapy induction strategy. Translational Cancer Research, 2023, .	0.4	0
1124	Immunotherapy May Improve Tumor Sensitivity to Palliative Chemotherapy in Platinum Resistant Ovarian Cancer. Oncologist, 2023, 28, e478-e486.	1.9	1

#	Article	IF	Citations
1125	Dynamics and specificities of T cells in cancer immunotherapy. Nature Reviews Cancer, 2023, 23, 295-316.	12.8	49
1126	Changes of peripheral T cell subsets in melanoma patients with immune-related adverse events. Frontiers in Immunology, 0, 14, .	2.2	0
1127	Phenotypic plasticity and reduced tissue retention of exhausted tumor-infiltrating TÂcells following neoadjuvant immunotherapy in head and neck cancer. Cancer Cell, 2023, 41, 887-902.e5.	7.7	13
1128	Responsive manganese-based nanoplatform amplifying cGAS-STING activation for immunotherapy. Biomaterials Research, 2023, 27, .	3.2	3
1129	Assessment of the Association between Entropy in PET/CT and Response to Anti-PD-1/PD-L1 Monotherapy in Stage III or IV NSCLC. Life, 2023, 13, 1051.	1.1	1
1130	Metastatic sites and lesion numbers cooperated to predict efficacy of <scp>PD</scp> â€1 inhibitorâ€based combination therapy for patients with metastatic colorectal cancer. Cancer Medicine, 0, , .	1.3	0
1156	T cells in health and disease. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	36
1171	From mucosal infection to successful cancer immunotherapy. Nature Reviews Urology, 0, , .	1.9	2
1191	Stem-like exhausted and memory CD8+ T cells in cancer. Nature Reviews Cancer, 2023, 23, 780-798.	12.8	5
1219	Understanding immune checkpoints and PD-1/PD-L1-mediated immune resistance towards tumour immunotherapy. 3 Biotech, 2023, 13, .	1.1	0
1228	Management of melanoma: can we use gene expression profiling to help guide treatment and surveillance?. Clinical and Experimental Metastasis, 0, , .	1.7	0
1246	Cancer immunotherapy-associated endocrine complications and treatment strategies. , 2024, , 199-221.		0
1277	Current and Future Perspectives of Combining Chemotherapy and Stereotactic Body Radiation Therapy with Immunotherapy in the Treatment of Lung Cancer. , 2024, , 265-295.		0